<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Endocrinol (Lausanne)</journal-id><journal-id journal-id-type="iso-abbrev">Front Endocrinol (Lausanne)</journal-id><journal-id journal-id-type="pmc-domain-id">1753</journal-id><journal-id journal-id-type="pmc-domain">frontendo</journal-id><journal-id journal-id-type="publisher-id">Front. Endocrinol.</journal-id><journal-title-group><journal-title>Frontiers in Endocrinology</journal-title></journal-title-group><issn pub-type="epub">1664-2392</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11184125</article-id><article-id pub-id-type="pmcid-ver">PMC11184125.1</article-id><article-id pub-id-type="pmcaid">11184125</article-id><article-id pub-id-type="pmcaiid">11184125</article-id><article-id pub-id-type="pmid">38894738</article-id><article-id pub-id-type="doi">10.3389/fendo.2024.1366935</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Endocrinology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Comparative analysis through propensity score matching in thyroid cancer: unveiling the impact of multiple malignancies</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Al-Ibraheem</surname><given-names initials="A">Akram</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/472825"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Abdlkadir</surname><given-names initials="AS">Ahmed Saad</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2138593"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Al-Adhami</surname><given-names initials="DA">Dhuha Ali</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lopci</surname><given-names initials="E">Egesta</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/604319"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Al-Omari</surname><given-names initials="A">Amal</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2624015"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Al-Masri</surname><given-names initials="M">Mahmoud</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1016780"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yousef</surname><given-names initials="Y">Yacoub</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1241366"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Al-Hajaj</surname><given-names initials="N">Nabeela</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mohamad</surname><given-names initials="I">Issa</given-names></name><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1270625"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Singer</surname><given-names initials="S">Susanne</given-names></name><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sykiotis</surname><given-names initials="GP">Gerasimos P.</given-names></name><xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/769326"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Department of Nuclear Medicine, King Hussein Cancer Center (KHCC)</institution>, <addr-line>Amman</addr-line>, <country>Jordan</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Division of Nuclear Medicine, Department of Radiology and Nuclear Medicine, the University of Jordan</institution>, <addr-line>Amman</addr-line>, <country>Jordan</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Nuclear Medicine Unit, IRCCS&#8211; Humanitas Clinical and Research Hospital</institution>, <addr-line>Rozzano, Milan</addr-line>, <country>Italy</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>Office of Scientific Affairs and Research (OSAR), King Hussein Cancer Center (KHCC)</institution>, <addr-line>Amman</addr-line>, <country>Jordan</country>
</aff><aff id="aff5">
<sup>5</sup>
<institution>Department of Surgery, King Hussein Cancer Center (KHCC)</institution>, <addr-line>Amman</addr-line>, <country>Jordan</country>
</aff><aff id="aff6">
<sup>6</sup>
<institution>Department of Radiation Oncology, King Hussein Cancer Center (KHCC)</institution>, <addr-line>Amman</addr-line>, <country>Jordan</country>
</aff><aff id="aff7">
<sup>7</sup>
<institution>Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Centre Mainz</institution>, <addr-line>Mainz</addr-line>, <country>Germany</country>
</aff><aff id="aff8">
<sup>8</sup>
<institution>Department of Endocrinology, Diabetology and Metabolism, Vaud University Hospital Center (CHUV)</institution>, <addr-line>Lausanne</addr-line>, <country>Switzerland</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Theodora Pappa, Brigham and Women&#8217;s Hospital and Harvard Medical School, United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Kyriakos Vamvakidis, Henry Dunant Hospital, Greece</p><p>Akira Sugawara, Tohoku University, Japan</p><p>Marta Villanova, San Raffaele Hospital (IRCCS), Italy</p><p>Francesca Perticone, Vita-Salute San Raffaele University, Italy</p></fn><corresp id="fn001">*Correspondence: Akram Al-Ibraheem, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:aibraheem@khcc.jo">aibraheem@khcc.jo</email>; <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:akramalibrahim@gmail.com">akramalibrahim@gmail.com</email></corresp><fn fn-type="other" id="fn003"><p>&#8224;ORCID: Akram Al-Ibraheem, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0002-0978-4716">orcid.org/0000-0002-0978-4716</uri>
</p></fn></author-notes><pub-date pub-type="epub"><day>04</day><month>6</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">454534</issue-id><elocation-id>1366935</elocation-id><history><date date-type="received"><day>07</day><month>1</month><year>2024</year></date><date date-type="accepted"><day>22</day><month>5</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>18</day><month>06</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-05-01 19:26:53.590"><day>01</day><month>05</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2024 Al-Ibraheem, Abdlkadir, Al-Adhami, Lopci, Al-Omari, Al-Masri, Yousef, Al-Hajaj, Mohamad, Singer and Sykiotis</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Al-Ibraheem, Abdlkadir, Al-Adhami, Lopci, Al-Omari, Al-Masri, Yousef, Al-Hajaj, Mohamad, Singer and Sykiotis</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fendo-15-1366935.pdf"/><abstract><sec><title>Background</title><p>The incidence of thyroid cancer is on the rise worldwide, with childhood exposure to radiation being the sole acknowledged catalyst for its emergence. Nonetheless, numerous other factors that may pose risks are awaiting thorough examination and validation. This retrospective study aims to explore the malignancies linked to thyroid cancer and contrast the survival rates of those afflicted with a solitary tumor versus those with multiple primary neoplasms (MPN).</p></sec><sec><title>Methods</title><p>This retrospective study examined data from King Hussein Cancer Center (KHCC), Jordan. Among 563 patients diagnosed with thyroid cancer, 30 patients had thyroid malignancy as part of MPN. For a 1:3 propensity score-matched analysis, 90 patients with only a primary thyroid malignancy were also enrolled.</p></sec><sec><title>Results</title><p>Hematologic and breast malignancies were among the most frequent observed cancers alongside thyroid neoplasm. Patients who had MPN were diagnosed at older age, had higher body mass index and presented with higher thyroglobulin antibody levels (<italic toggle="yes">p</italic> &lt; 0.05 for each). Additionally, MPN patient displayed a stronger family history for cancers (<italic toggle="yes">p</italic>= 0.002). A median follow-up duration of 135 months unveiled that MPN patients faced a worse 5-year survival compared to their counterparts with a singular neoplasm (87% vs 100% respectively; p &lt; 0.01). However, no distinction emerged in the 5-year event-free survival between these two groups.</p></sec><sec><title>Conclusion</title><p>MPN correlates with a significantly altered survival outcome of thyroid cancer patients. The diagnosis of thyroid carcinoma at an older age, accompanied by elevated initial thyroglobulin antibody levels and a notable familial predisposition, may raise concerns about the potential occurrence of synchronous or metachronous tumors.</p></sec></abstract><kwd-group><kwd>thyroid carcinoma</kwd><kwd>multiple primary neoplasms</kwd><kwd>survival analysis</kwd><kwd>prognosis</kwd><kwd>multiple primary malignancies</kwd><kwd>multiple primary cancers</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.</funding-statement></funding-group><counts><fig-count count="1"/><table-count count="5"/><equation-count count="0"/><ref-count count="80"/><page-count count="12"/><word-count count="5281"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Cancer Endocrinology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><label>1</label><title>Introduction</title><p>Thyroid cancer (TC) constitutes 1% of all cancer cases (<xref rid="B1" ref-type="bibr">1</xref>&#8211;<xref rid="B5" ref-type="bibr">5</xref>). The incidence of TC has been increasing in most populations worldwide (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>). This increase may be attributed to advancements in clinical practices and/or changes in histological criteria, as well as potential alterations in environmental and hormonal factors (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>). While TC is generally more prevalent in females, males have a higher likelihood of having a positive family history of malignancy (<xref rid="B10" ref-type="bibr">10</xref>). Treatment options for TC vary depending on the histology and extent of the disease, encompassing surgical intervention, radioactive iodine therapy, suppressive thyroid hormone therapy, and occasionally, external beam radiotherapy (<xref rid="B11" ref-type="bibr">11</xref>). Despite acknowledged ethnic variations, the prognosis for treated TC is favorable, with excellent overall survival (OS) rates (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B12" ref-type="bibr">12</xref>&#8211;<xref rid="B14" ref-type="bibr">14</xref>).</p><p>When considering the histologic subtypes, TC can be divided into five unique classifications: papillary TC (PTC), follicular TC (FTC), medullary TC (MTC), anaplastic TC, and miscellaneous subtypes (<xref rid="B15" ref-type="bibr">15</xref>). It is worth noting that the majority of TC, around 95%, originates from the follicular epithelium, manifesting in PTC, FTC, and anaplastic variations (<xref rid="B16" ref-type="bibr">16</xref>). In numerous surveyed countries, the most prevalent subtype is PTC, accounting for 70% or more of cases (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B18" ref-type="bibr">18</xref>). The prognosis is highly favorable for PTC and FTC, whereas other histologic subtypes demonstrate a poorer prognosis and limited therapeutic options (<xref rid="B19" ref-type="bibr">19</xref>&#8211;<xref rid="B22" ref-type="bibr">22</xref>).</p><p>As the early cancer detection becomes more common, individuals who survive this disease are living longer, which may increase the risk of developing multiple primary neoplasms (MPN) (<xref rid="B23" ref-type="bibr">23</xref>). A limited number of investigations have been conducted to examine the potential risk of developing a second neoplasm following a diagnosis of TC, including comprehensive studies conducted in Europe and the United States (<xref rid="B24" ref-type="bibr">24</xref>&#8211;<xref rid="B28" ref-type="bibr">28</xref>). These studies have consistently demonstrated a rise in the occurrence of cancers subsequent to TC diagnosis. Additionally, it has been observed that TC can be diagnosed as a second primary neoplasm subsequent to other forms of cancer (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B29" ref-type="bibr">29</xref>&#8211;<xref rid="B32" ref-type="bibr">32</xref>).</p><p>The present study aimed to examine the cancers associated with TC and to compare survival rates between patients with thyroid-only cancers and patients with thyroid cancer as part of MPN. This may help shed light on common etiological factors affecting such a challenging group of patients.</p></sec><sec sec-type="materials|methods" id="s2"><label>2</label><title>Materials and methods</title><sec id="s2_1"><label>2.1</label><title>Data collection</title><p>The medical records of 563 patients diagnosed with TC between September 1998 and December 2021 were retrospectively enrolled. For these patients, demographic data were collected and included age at diagnosis and patient gender. In addition, pathological data included cancer site, cancer type, cancer grade, and cancer stage according to the American Joint Committee on Cancer 8th Edition (AJCC 8th) (<xref rid="B33" ref-type="bibr">33</xref>). Moreover, the baseline postoperative levels for serum thyroglobulin and thyroglobulin antibodies were collected (<xref rid="B34" ref-type="bibr">34</xref>). Other important details include a history of MPN.</p><p>The diagnosis of MPN relies on the criteria put forth by Warren et&#160;al. in 1933 (<xref rid="B35" ref-type="bibr">35</xref>), which require histopathological confirmation. Furthermore, each individual cancer included in MPN must be identifiable as separate from the surrounding normal mucosa (<xref rid="B35" ref-type="bibr">35</xref>). Last, the possibility of the second neoplasm being metastatic should be excluded (<xref rid="B35" ref-type="bibr">35</xref>). For those patients, another round of pathological analysis was performed for other cancer subtypes in addition to ranking each and every subtype along with labeling the date of diagnosis for each cancer. According to the criteria set forth by the International Association of Cancer Registries and the International Agency for Research on Cancer (IACR/IARC), synchronous MPN are defined as the diagnosis of two or more primary malignancies within a 6-month timeframe (<xref rid="B36" ref-type="bibr">36</xref>). In contrast, metachronous MPN pertain to the presence of more than two primary malignancies emerging beyond the 6-month timeframe (<xref rid="B36" ref-type="bibr">36</xref>).</p><p>To refine our investigation, the study cohort was further segmented into two distinct groups. The first group consisted of patients diagnosed with MPN who had TC as a component of their MPN (n = 30). A 1:3 propensity score matching strategy was utilized to select a comparable group of patients with only TC. This technique sought to identify individuals with similar characteristics, including gender, chronic diseases (namely diabetes mellitus, hypertension, and dyslipidemia), type of thyroid cancer, and stage. By employing this propensity score matching approach, our objective was to mitigate the influence of any factors that could potentially influence the outcomes. As a result, a cohort of 120 patients was obtained for subsequent analysis.</p><p>In light of the absence of a comprehensive genetic analysis within our examined cohort, a meticulous screening process of patient records was undertaken to eliminate subjects exhibiting indications of syndromic manifestations elucidated by V&#226;nia Nos&#233; (<xref rid="B37" ref-type="bibr">37</xref>). These manifestations encompass, among others, Multiple Endocrine Neoplasia Type 2, Cowden Syndrome, Familial Adenomatous Polyposis, Carney Complex, and Werner Syndrome (<xref rid="B37" ref-type="bibr">37</xref>). Notably, there were no instances of patients presenting with the mentioned syndromes in our studied population.</p></sec><sec id="s2_2"><label>2.2</label><title>Ethics consideration</title><p>This retrospective study received its approval from the Institutional Review Board of King Hussein Cancer Center (KHCC) in Amman, Jordan (Registration number: 22 KHCC 131, 11 August 2022). Written informed consent for this study was not needed due to its retrospective nature.</p></sec><sec id="s2_3"><label>2.3</label><title>Statistical analysis</title><p>The statistical analysis was conducted using Stata software version 17 (College Station, TX, USA). To determine the data distribution, a normality test called Shapiro Wilk was utilized. Normally distributed variables were presented as the mean &#177; standard deviation (SD). The median and interquartile range (IQR) were expressed for variables that did not have a normal distribution. Normally distributed variables are presented as the mean &#177; standard deviation (SD). The frequencies of categorical variables were represented by percentages (%). To analyze categorical variables, we used either the chi squared test or Fisher exact test while the nonparametric Mann Whitney U test or t-test were used to analyze continuous variables based on their appropriateness. Kaplan&#8722;Meier plots and log-rank tests were utilized to illustrate the survival curves. cancer-specific OS and event-free survival (EFS) were calculated. First, we conducted an analysis focused on cancer-specific OS and EFS. In this context, cancer-related OS was defined as the interval from the time of initial diagnosis to the point of death directly attributed to any cancer subtype. Instances of death resulting from unrelated causes were censored. In the same manner, cancer-specific EFS was delineated as the span from the time of diagnosis to the advent of advancing, or recurring cancer. Subsequently, an examination of univariate and multivariate Cox proportional hazard analysis was undertaken to investigate the predictive weight of diverse clinicopathologic factors. A significance threshold of less than 0.05 (<italic toggle="yes">p</italic> &lt; 0.05) was deemed statistically significant.</p></sec></sec><sec sec-type="results" id="s3"><label>3</label><title>Results</title><p>This retrospective study utilized KHCC cohort of TC patients to explore patients who had MPN. A total of 30 patients were identified with MPN. Those patients were observed to have 68 neoplasms in total. Thirty-one of these were thyroid neoplasms and the remaining 37 were other malignancies. Demographic and clinicopathologic characteristics are shown in <xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table&#160;1</label><caption><p>Demographic and histopathologic characteristics for patients with multiple neoplasms.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="2" align="center" rowspan="1">Demographics</th></tr></thead><tbody><tr><th valign="top" colspan="2" align="left" rowspan="1">Age (in Years)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Median</td><td valign="top" align="left" rowspan="1" colspan="1">54 years</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Interquartile Range</td><td valign="top" align="left" rowspan="1" colspan="1">42&#8211;64 years</td></tr><tr><th valign="top" colspan="2" align="left" rowspan="1">Gender (Number of Patients, Percentage)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Male</td><td valign="top" align="left" rowspan="1" colspan="1">14, 47%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Female</td><td valign="top" align="center" rowspan="1" colspan="1">16, 53%</td></tr><tr><th valign="top" colspan="2" align="left" rowspan="1">Thyroid Cancer (Total Neoplasms= 31)</th></tr><tr><th valign="top" colspan="2" align="left" rowspan="1">Histopathologic Subtype (Number of Thyroid Neoplasms, Percentage)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Papillary</td><td valign="top" align="left" rowspan="1" colspan="1">24, 77.3%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Follicular</td><td valign="top" align="left" rowspan="1" colspan="1">2, 6.5%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hurthle</td><td valign="top" align="left" rowspan="1" colspan="1">2, 6.5%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Medullary</td><td valign="top" align="left" rowspan="1" colspan="1">3, 9.7%</td></tr><tr><th valign="top" colspan="2" align="left" rowspan="1">Cancer Stage (Number of Thyroid Neoplasms, Percentage)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Stage I</td><td valign="top" align="left" rowspan="1" colspan="1">20, 64.5</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Stage II</td><td valign="top" align="left" rowspan="1" colspan="1">10, 32.3%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Stage III</td><td valign="top" align="left" rowspan="1" colspan="1">1, 3.2%</td></tr><tr><th valign="top" colspan="2" align="left" rowspan="1">Triggers for thyroid cancer discovery (Number of Patients, Percentage)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Discovered following neck swelling</td><td valign="top" align="left" rowspan="1" colspan="1">9, 30%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Discovered incidentally during whole-body imaging</td><td valign="top" align="left" rowspan="1" colspan="1">8, 26.7%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Discovered before referral to our institute</td><td valign="top" align="left" rowspan="1" colspan="1">4, 13.3%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Diagnosed by an outside institute</td><td valign="top" align="left" rowspan="1" colspan="1">4, 13.3%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Incidental discovery on histopathologic examination after surgical removal of ipsilateral thyroid lobe adjacent to the resected tumor of interest</td><td valign="top" align="left" rowspan="1" colspan="1">3, 10%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Subclinical hypothyroidism and ultrasound finding of thyroid nodule</td><td valign="top" align="left" rowspan="1" colspan="1">2, 6.7%</td></tr><tr><th valign="top" colspan="2" align="left" rowspan="1">Prior radiation before thyroid cancer diagnosis (Number of Patients, Percentage)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Neck Radiotherapy</td><td valign="top" align="left" rowspan="1" colspan="1">3, 10%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Diagnostic whole-body Computed tomography</td><td valign="top" align="left" rowspan="1" colspan="1">16, 53.3%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Diagnostic whole-body Positron emission tomography/computed tomography</td><td valign="top" align="left" rowspan="1" colspan="1">9, 30%</td></tr><tr><th valign="top" colspan="2" align="left" rowspan="1">Surgical Intervention (Number of Patients, Percentage)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Total Thyroidectomy</td><td valign="top" align="left" rowspan="1" colspan="1">25, 83.3%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Thyroid lobectomy followed by completion thyroidectomy</td><td valign="top" align="left" rowspan="1" colspan="1">3, 10%</td></tr><tr><th valign="top" colspan="2" align="left" rowspan="1">Radioactive Iodine (Number, Percentage)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Number of patients, percentage</td><td valign="top" align="left" rowspan="1" colspan="1">27, 90%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cumulative dose (Median, Interquartile Range)</td><td valign="top" align="left" rowspan="1" colspan="1">2.4 GBq (1.1&#8211;5.9 GBq)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Doses Received (Mean, Standard Deviation)</td><td valign="top" align="left" rowspan="1" colspan="1">1 &#177; 1</td></tr><tr><th valign="top" colspan="2" align="left" rowspan="1">Interval days between total thyroidectomy and radioactive iodine</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Median</td><td valign="top" align="left" rowspan="1" colspan="1">29</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Interquartile range</td><td valign="top" align="left" rowspan="1" colspan="1">17&#8211;96</td></tr><tr><th valign="top" colspan="2" align="center" rowspan="1">Other Malignancies (Total Neoplasms= 37)</th></tr><tr><th valign="top" colspan="2" align="left" rowspan="1">Classification (Number of Patients, Percentage)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Synchronous only</td><td valign="top" align="left" rowspan="1" colspan="1">10, 33.3%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Metachronous</td><td valign="top" align="left" rowspan="1" colspan="1">20, 66.7%</td></tr><tr><th valign="top" colspan="2" align="left" rowspan="1">Cancer Stage (Number of Neoplasms, Percentage)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Stage I</td><td valign="top" align="left" rowspan="1" colspan="1">10, 27%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Stage II</td><td valign="top" align="left" rowspan="1" colspan="1">11, 29.7%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Stage III</td><td valign="top" align="left" rowspan="1" colspan="1">9, 24.3%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Stage IV</td><td valign="top" align="left" rowspan="1" colspan="1">7, 19%</td></tr></tbody></table></table-wrap><sec id="s3_1"><label>3.1</label><title>Patients with multiple primary neoplasms</title><sec id="s3_1_1"><label>3.1.1</label><title>Incidence</title><p>Between September 1998 and December 2021, of 563 TC patients, 533 patients (95%) had a single thyroid neoplasm. The remaining 30 patients (5%) were diagnosed with MPN. For patients with MPN, a total of 24 patients had two primary neoplasms. In addition, a total of four patients presented with three neoplasms while only two patients had four neoplasms.</p></sec><sec id="s3_1_2"><label>3.1.2</label><title>Temporal presentation</title><p>The median interval between first and second primary neoplasms was 13 months with an IQR of 2&#8211;46 months. Of all 30 patients diagnosed with MPN, only one third (n= 10) had synchronous malignancies. The remaining 20 patients had metachronous MPN. TC was the first diagnosed neoplasm in eight patients. However, all remaining patients were diagnosed with TC subsequent to their initial primary neoplasm (<xref rid="T2" ref-type="table">
<bold>Table&#160;2</bold>
</xref>).</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table&#160;2</label><caption><p>Summary table for the identified cancer subtypes in patients with multiple neoplasms.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="5" align="center" rowspan="1">Coexisting Neoplasm Discovered Concomitantly</th></tr><tr><th valign="top" align="center" rowspan="1" colspan="1">#</th><th valign="top" align="center" rowspan="1" colspan="1">First Neoplasm</th><th valign="top" colspan="3" align="center" rowspan="1">Coexisting Neoplasms</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>1</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Medullary Thyroid Cancer</td><td valign="top" colspan="3" align="left" rowspan="1">Parathyroid Carcinoma</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>2</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Papillary Thyroid Cancer</td><td valign="top" colspan="3" align="left" rowspan="1">Hurthle Cell Neoplasm of the Thyroid</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>3</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Papillary Thyroid Cancer</td><td valign="top" colspan="3" align="left" rowspan="1">Laryngeal Squamous Carcinoma of Subglottis</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>4</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Papillary Thyroid Cancer</td><td valign="top" colspan="3" align="left" rowspan="1">Laryngeal Squamous Carcinoma of Epiglottis</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>5</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Papillary Thyroid Cancer</td><td valign="top" colspan="3" align="left" rowspan="1">Malignant Melanoma</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>6</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Invasive Lobular Carcinoma of right Breast</td><td valign="top" colspan="3" align="left" rowspan="1">Invasive Cribriform Carcinoma of left Breast</td></tr><tr><th valign="top" colspan="5" align="center" rowspan="1">Other Synchronous Neoplasm</th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1">First Neoplasm</th><th valign="top" align="left" rowspan="1" colspan="1">Second Neoplasm</th><th valign="top" colspan="2" align="left" rowspan="1">Interval Between Both neoplasms</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>7</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Hodgkin&#8217;s Lymphoma</td><td valign="top" align="left" rowspan="1" colspan="1">Hurthle Cell Neoplasm of the Thyroid</td><td valign="top" colspan="2" align="left" rowspan="1">1 Month</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>8</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Papillary Thyroid Cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Prostate Cancer</td><td valign="top" colspan="2" align="left" rowspan="1">1 Month</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>9</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Invasive Lobular Carcinoma of Breast</td><td valign="top" align="left" rowspan="1" colspan="1">Papillary Thyroid Cancer</td><td valign="top" colspan="2" align="left" rowspan="1">3 Months</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>10</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Nasopharyngeal Carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">Medullary Thyroid Cancer</td><td valign="top" colspan="2" align="left" rowspan="1">5 Months</td></tr><tr><th valign="top" colspan="5" align="center" rowspan="1">Patients with Metachronous Malignancies</th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">#</th><th valign="top" align="left" rowspan="1" colspan="1">First Neoplasm</th><th valign="top" align="left" rowspan="1" colspan="1">Second Neoplasm</th><th valign="top" align="left" rowspan="1" colspan="1">Third Neoplasm</th><th valign="top" align="left" rowspan="1" colspan="1">Fourth Neoplasm</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>1</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Malignant Ovarian Teratoma</td><td valign="top" align="left" rowspan="1" colspan="1">Follicular Thyroid Cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Papillary Urothelial Carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>2</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Papillary Thyroid Cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Invasive Ductal Carcinoma of Breast</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>3</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Cecal Adenocarcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">Papillary Thyroid Cancer</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>4</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Papillary Thyroid Cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Chordoma</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>5</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Papillary Thyroid Cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Invasive Ductal Carcinoma of Breast</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>6</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Invasive Ductal Carcinoma of Breast</td><td valign="top" align="left" rowspan="1" colspan="1">Papillary Thyroid Cancer</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>7</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Papillary Thyroid Cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Ileal neuroendocrine Tumor</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>8</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Papillary Thyroid Cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Lung Adenocarcinoma</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>9</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">AML</td><td valign="top" align="left" rowspan="1" colspan="1">DLBCL</td><td valign="top" align="left" rowspan="1" colspan="1">Papillary Thyroid Cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Oral SCC</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>10</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Invasive Ductal Carcinoma of Breast</td><td valign="top" align="left" rowspan="1" colspan="1">Papillary Thyroid Cancer</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>11</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Papillary Thyroid Cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Gastric Adenocarcinoma</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>12</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Hodgkin&#8217;s Lymphoma</td><td valign="top" align="left" rowspan="1" colspan="1">Papillary Thyroid Cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Leiomyosarcoma of Urinary Bladder</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>13</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Jejunal GIST</td><td valign="top" align="left" rowspan="1" colspan="1">Papillary Thyroid Cancer</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>14</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Adenocarcinoma of Gallbladder</td><td valign="top" align="left" rowspan="1" colspan="1">Papillary Thyroid Cancer</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>15</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Colorectal Cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Papillary Thyroid Cancer</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>16</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Follicular Lymphoma</td><td valign="top" align="left" rowspan="1" colspan="1">Papillary Thyroid Cancer</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>17</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Maxillary Sinus SCC</td><td valign="top" align="left" rowspan="1" colspan="1">Follicular Thyroid Cancer</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>18</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">DLBCL</td><td valign="top" align="left" rowspan="1" colspan="1">Follicular Lymphoma</td><td valign="top" align="left" rowspan="1" colspan="1">Papillary Thyroid Cancer</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>19</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">DLBCL</td><td valign="top" align="left" rowspan="1" colspan="1">Medullary Thyroid Cancer</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>20</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Papillary Thyroid Cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Invasive Ductal Carcinoma of Breast</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><th valign="top" colspan="5" align="center" rowspan="1">Dual-timing malignancy cases (Cases with Metachronous and Synchronous Cancers)</th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">#</th><th valign="top" align="left" rowspan="1" colspan="1">Metachronous neoplasms</th><th valign="top" colspan="5" align="left" rowspan="1">Synchronous Neoplasms</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>1</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Basal cell carcinoma of Scalp &#8594; First Detected Neoplasm<break/>Papillary Thyroid Cancer &#8594; Fourth Neoplasm</td><td valign="top" colspan="5" align="left" rowspan="1">ILC of right breast coexisting with ICC of left breast</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>2</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Renal Cell Carcinoma of right Kidney &#8594; Third neoplasm</td><td valign="top" colspan="5" align="left" rowspan="1">Hodgkin&#8217;s Lymphoma &#8594; First neoplasm<break/>Hurtle Cell Neoplasm &#8594; Second Neoplasm</td></tr></tbody></table></table-wrap></sec><sec id="s3_1_3"><label>3.1.3</label><title>Thyroid cancer subtypes</title><p>In all 30 patients presented with MPN, a total of 31 TC neoplasms were observed. Approximately, 24 patients had an established diagnosis of PTC as the predominant histopathologic subtype (n= 24). Follicular and hurtle subtypes were found in 2 patients each. In addition, MTC was diagnosed in 3 patients (<xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>). It is noteworthy that one of our MPN patients had an established diagnosis of both synchronous Hurthle and papillary subtypes (<xref rid="T2" ref-type="table">
<bold>Table&#160;2</bold>
</xref>).</p></sec><sec id="s3_1_4"><label>3.1.4</label><title>Coexisting malignancies: by region</title><p>A total of 37 coexisting malignancies were observed. Notably, hematologic and breast malignancies were among the most common identifiable coexisting malignancies in patients with MPN (n=8 for each). This was followed by head and neck cancers (n=6). Then an equivalent number of patients who had gastrointestinal and genitourinary malignancies were identified (n= 5 for each). Other cancer subtypes followed in predominance (<xref rid="T3" ref-type="table">
<bold>Table&#160;3</bold>
</xref>).</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table&#160;3</label><caption><p>Region-based summarization of the identified cancer subtypes in patients with multiple neoplasms.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="4" align="center" rowspan="1">Hematologic Malignancies</th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Site</th><th valign="top" align="left" rowspan="1" colspan="1">Histopathology</th><th valign="top" align="left" rowspan="1" colspan="1">Number (Percentage)</th><th valign="top" align="left" rowspan="1" colspan="1">Cancer Stage (Number)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Cervical Lymph node</td><td valign="top" align="left" rowspan="1" colspan="1">DLBCL</td><td valign="top" align="left" rowspan="1" colspan="1">3 (10%)</td><td valign="top" align="left" rowspan="1" colspan="1">II (n=2); IV (n=1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">AML</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3%)</td><td valign="top" align="left" rowspan="1" colspan="1">M1 (n=1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">HL</td><td valign="top" align="left" rowspan="1" colspan="1">2 (6.7%)</td><td valign="top" align="left" rowspan="1" colspan="1">II (n=1); III (n=1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">FL</td><td valign="top" align="left" rowspan="1" colspan="1">2 (6.7%)</td><td valign="top" align="left" rowspan="1" colspan="1">II (n=1); IV (n=1)</td></tr><tr><th valign="top" colspan="4" align="center" rowspan="1">Head and Neck Cancers</th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Site</th><th valign="top" align="left" rowspan="1" colspan="1">Histopathology</th><th valign="top" align="left" rowspan="1" colspan="1">Number (Percentage)</th><th valign="top" align="left" rowspan="1" colspan="1">Cancer Stage (Number)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Larynx</td><td valign="top" align="left" rowspan="1" colspan="1">SCC</td><td valign="top" align="left" rowspan="1" colspan="1">2 (6.7%)</td><td valign="top" align="left" rowspan="1" colspan="1">III (n=2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Parathyroid Carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">Parathyroid Carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3%)</td><td valign="top" align="left" rowspan="1" colspan="1">II (n=1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Oral SCC</td><td valign="top" align="left" rowspan="1" colspan="1">SCC</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3%)</td><td valign="top" align="left" rowspan="1" colspan="1">IV (n=1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Maxillary sinus SCC</td><td valign="top" align="left" rowspan="1" colspan="1">SCC</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3%)</td><td valign="top" align="left" rowspan="1" colspan="1">III (n=1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Nasopharynx</td><td valign="top" align="left" rowspan="1" colspan="1">Nasopharyngeal Carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3%)</td><td valign="top" align="left" rowspan="1" colspan="1">III (n=1)</td></tr><tr><th valign="top" colspan="4" align="center" rowspan="1">Breast</th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Site</th><th valign="top" align="left" rowspan="1" colspan="1">Histopathology</th><th valign="top" align="left" rowspan="1" colspan="1">Number (Percentage)</th><th valign="top" align="left" rowspan="1" colspan="1">Cancer Stage (Number)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Left Breast</td><td valign="top" align="left" rowspan="1" colspan="1">IDC</td><td valign="top" align="left" rowspan="1" colspan="1">3 (10%)</td><td valign="top" align="left" rowspan="1" colspan="1">I (n=2); II (n=1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Right Breast</td><td valign="top" align="left" rowspan="1" colspan="1">IDC</td><td valign="top" align="left" rowspan="1" colspan="1">3 (10%)</td><td valign="top" align="left" rowspan="1" colspan="1">II (n=3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Right Breast</td><td valign="top" align="left" rowspan="1" colspan="1">ILC</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3%)</td><td valign="top" align="left" rowspan="1" colspan="1">I (n=1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Left Breast</td><td valign="top" align="left" rowspan="1" colspan="1">ICC</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3%)</td><td valign="top" align="left" rowspan="1" colspan="1">I (n=1)</td></tr><tr><th valign="top" colspan="4" align="center" rowspan="1">Gastrointestinal Malignancies</th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Site</th><th valign="top" align="left" rowspan="1" colspan="1">Histopathology</th><th valign="top" align="left" rowspan="1" colspan="1">Number (Percentage)</th><th valign="top" align="left" rowspan="1" colspan="1">Cancer Stage (Number)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Colorectal</td><td valign="top" align="left" rowspan="1" colspan="1">Adenocarcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3%)</td><td valign="top" align="left" rowspan="1" colspan="1">II (n=1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cecal</td><td valign="top" align="left" rowspan="1" colspan="1">Adenocarcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3%)</td><td valign="top" align="left" rowspan="1" colspan="1">III (n=1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ileum</td><td valign="top" align="left" rowspan="1" colspan="1">NET</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3%)</td><td valign="top" align="left" rowspan="1" colspan="1">III (n=1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Jejunum</td><td valign="top" align="left" rowspan="1" colspan="1">GIST</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3%)</td><td valign="top" align="left" rowspan="1" colspan="1">IV (n=1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Stomach</td><td valign="top" align="left" rowspan="1" colspan="1">Adenocarcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3%)</td><td valign="top" align="left" rowspan="1" colspan="1">IV (n=1)</td></tr><tr><th valign="top" colspan="4" align="center" rowspan="1">Genitourinary Malignancies</th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Site</th><th valign="top" align="left" rowspan="1" colspan="1">Histopathology</th><th valign="top" align="left" rowspan="1" colspan="1">Number (Percentage)</th><th valign="top" align="left" rowspan="1" colspan="1">Cancer Stage (Number)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Left Ovary</td><td valign="top" align="left" rowspan="1" colspan="1">Immature malignant Teratoma</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3%)</td><td valign="top" align="left" rowspan="1" colspan="1">I (n=1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Urinary Bladder</td><td valign="top" align="left" rowspan="1" colspan="1">Papillary Urothelial Carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3%)</td><td valign="top" align="left" rowspan="1" colspan="1">III (n=1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Urinary Bladder</td><td valign="top" align="left" rowspan="1" colspan="1">Leiomyosarcoma</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3%)</td><td valign="top" align="left" rowspan="1" colspan="1">II (n=1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Prostate</td><td valign="top" align="left" rowspan="1" colspan="1">Adenocarcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3%)</td><td valign="top" align="left" rowspan="1" colspan="1">IV (n=1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Kidney</td><td valign="top" align="left" rowspan="1" colspan="1">RCC</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3%)</td><td valign="top" align="left" rowspan="1" colspan="1">I (n=1)</td></tr><tr><th valign="top" colspan="4" align="center" rowspan="1">Other Cancers</th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Site</th><th valign="top" align="left" rowspan="1" colspan="1">Histopathology</th><th valign="top" align="left" rowspan="1" colspan="1">Number (Percentage)</th><th valign="top" align="left" rowspan="1" colspan="1">Cancer Stage (Number)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Left Lower Lung Lobe</td><td valign="top" align="left" rowspan="1" colspan="1">Adenocarcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3%)</td><td valign="top" align="left" rowspan="1" colspan="1">I (n=1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Skin (Right Inguinal Area)</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3%)</td><td valign="top" align="left" rowspan="1" colspan="1">III (n=1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Skin (Right Medial Canthus)</td><td valign="top" align="left" rowspan="1" colspan="1">Basal Cell Carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3%)</td><td valign="top" align="left" rowspan="1" colspan="1">I (n=1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">T3 Vertebra</td><td valign="top" align="left" rowspan="1" colspan="1">Chordoma</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3%)</td><td valign="top" align="left" rowspan="1" colspan="1">IV (n=1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gallbladder</td><td valign="top" align="left" rowspan="1" colspan="1">Adenocarcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3%)</td><td valign="top" align="left" rowspan="1" colspan="1">I (n=1)</td></tr></tbody></table></table-wrap></sec></sec><sec id="s3_2"><label>3.2</label><title>Propensity score matching</title><p>As stated before, 1:3 propensity score matching was performed to observe differences in clinical factors and survival outcomes between the two matched subgroups.</p><sec id="s3_2_1"><label>3.2.1</label><title>Differences between patients with single and multiple neoplasms</title><p>When comparing single thyroid neoplasm with MPN, patients who had TC as part of MPN were substantially older; the median age at diagnosis was 54 years vs 41 years for patients with single TC diagnosis (<italic toggle="yes">p</italic>= 0.04). They also had a higher body mass index (<italic toggle="yes">p</italic>= 0.003). In addition, they had a higher baseline thyroglobulin antibody (median value for MPN was 45.5 vs 11 for patients with single TC; <italic toggle="yes">p</italic>= 0.0003). Finally, a significantly higher percentage of patients had a positive family history of malignancy in patients diagnosed with MPN vs patients with a single TC (50% vs 20%; p= 0.002). Notably, the percentage of smokers, recurrence rates, mortality from TC, elapsed duration since postoperative thyroid markers conduction, and elapsed duration since initial TC diagnosis did not differ significantly when comparing both subgroups (<xref rid="T4" ref-type="table">
<bold>Table&#160;4</bold>
</xref>).</p><table-wrap position="float" id="T4" orientation="portrait"><label>Table&#160;4</label><caption><p>Clinicopathologic characteristics for patients with multiple neoplasms compared to those who had single thyroid malignancy.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Variable</th><th valign="top" align="left" rowspan="1" colspan="1">Multiple Neoplasm</th><th valign="top" align="left" rowspan="1" colspan="1">Single Neoplasm</th><th valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age at diagnosis (Years)</td><td valign="top" align="left" rowspan="1" colspan="1">54 (42&#8211;64)</td><td valign="top" align="left" rowspan="1" colspan="1">41 (24&#8211;60)</td><td valign="top" align="left" rowspan="1" colspan="1">0.04</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td valign="top" align="left" rowspan="1" colspan="1">27.1 (24.6&#8211;29.3)</td><td valign="top" align="left" rowspan="1" colspan="1">21 (20.5&#8211;23.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.003</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Smoking</td><td valign="top" align="left" rowspan="1" colspan="1">11 (36.7%)</td><td valign="top" align="left" rowspan="1" colspan="1">47 (51.1%)</td><td valign="top" align="left" rowspan="1" colspan="1">0.21</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Family History</td><td valign="top" align="left" rowspan="1" colspan="1">15 (50%)</td><td valign="top" align="left" rowspan="1" colspan="1">18 (20%)</td><td valign="top" align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Baseline Serum Thyroglobulin (ng/mL)</td><td valign="top" align="left" rowspan="1" colspan="1">13.1 (9.9&#8211;51.8)</td><td valign="top" align="left" rowspan="1" colspan="1">23.5 (9.8&#8211;66.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.32</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Baseline Thyroglobulin Antibody (ng/mL)</td><td valign="top" align="left" rowspan="1" colspan="1">45.5 (17&#8211;118)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (2&#8211;42)</td><td valign="top" align="left" rowspan="1" colspan="1">0.0003</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mortality from Thyroid cancer</td><td valign="top" align="left" rowspan="1" colspan="1">2 (6.7%)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (5.6%)</td><td valign="top" align="left" rowspan="1" colspan="1">0.99</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Thyroid cancer recurrence rates</td><td valign="top" align="left" rowspan="1" colspan="1">12 (40%)</td><td valign="top" align="left" rowspan="1" colspan="1">28 (31.1%)</td><td valign="top" align="left" rowspan="1" colspan="1">0.38</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Elapsed duration since initial postoperative thyroid marker conduction (years)</td><td valign="top" align="left" rowspan="1" colspan="1">5.7 (4&#8211;7.1)</td><td valign="top" align="left" rowspan="1" colspan="1">7.1 (5&#8211;8.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.28</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Elapsed duration since Thyroid cancer diagnosis (years)</td><td valign="top" align="left" rowspan="1" colspan="1">5.5 (4&#8211;7)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (5&#8211;8)</td><td valign="top" align="left" rowspan="1" colspan="1">0.22</td></tr></tbody></table></table-wrap></sec><sec id="s3_2_2"><label>3.2.2</label><title>Impact on survival</title><p>With regards to cancer-specific OS, patients with MPN had worse OS than those with TC alone. At a median follow-up of 135 months, MPN patients were found to have a poorer 5-year survival than patients with TC alone (<italic toggle="yes">p</italic> &lt; 0.01). However, the 5-year EFS was not significantly different between these two subcohorts (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>). Both univariate and multivariable Cox hazard models (<xref rid="T5" ref-type="table">
<bold>Table&#160;5</bold>
</xref>), suggest that the presence of MPN can have a negative effect on OS (<italic toggle="yes">p</italic>&#8804; 0.02).</p><fig position="float" id="f1" orientation="portrait"><label>Figure&#160;1</label><caption><p>Kaplan Meir Survival curves comparing <bold>(A)</bold> the cancer specific overall survival and <bold>(B)</bold> event-free survival for patient with multiple neoplasms vs those who had single thyroid malignancy.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fendo-15-1366935-g001.jpg"/></fig><table-wrap position="float" id="T5" orientation="portrait"><label>Table&#160;5</label><caption><p>Univariate and multivariate survival analyses for overall survival.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="4" align="center" rowspan="1">Univariate Analysis</th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Variable</th><th valign="top" align="left" rowspan="1" colspan="1">Hazard Ratio</th><th valign="top" align="left" rowspan="1" colspan="1">95% Confidence Interval</th><th valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age at diagnosis</td><td valign="top" align="left" rowspan="1" colspan="1">1.1</td><td valign="top" align="left" rowspan="1" colspan="1">0.9&#8211;1.2</td><td valign="top" align="left" rowspan="1" colspan="1">0.78</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Number of Neoplasms</td><td valign="top" align="left" rowspan="1" colspan="1">2.5</td><td valign="top" align="left" rowspan="1" colspan="1">1.1&#8211;5.1</td><td valign="top" align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Obesity</td><td valign="top" align="left" rowspan="1" colspan="1">0.4</td><td valign="top" align="left" rowspan="1" colspan="1">0.08&#8211;1.6</td><td valign="top" align="left" rowspan="1" colspan="1">0.16</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Smoking</td><td valign="top" align="left" rowspan="1" colspan="1">1.7</td><td valign="top" align="left" rowspan="1" colspan="1">0.4&#8211;8.3</td><td valign="top" align="left" rowspan="1" colspan="1">0.52</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Family History</td><td valign="top" align="left" rowspan="1" colspan="1">0.1</td><td valign="top" align="left" rowspan="1" colspan="1">0.1&#8211;65.3</td><td valign="top" align="left" rowspan="1" colspan="1">0.37</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Abnormal Serum Thyroglobulin</td><td valign="top" align="left" rowspan="1" colspan="1">1.1</td><td valign="top" align="left" rowspan="1" colspan="1">0.2&#8211;8.1</td><td valign="top" align="left" rowspan="1" colspan="1">0.89</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Abnormal Thyroglobulin Antibody</td><td valign="top" align="left" rowspan="1" colspan="1">1.2</td><td valign="top" align="left" rowspan="1" colspan="1">0.2&#8211;10.9</td><td valign="top" align="left" rowspan="1" colspan="1">0.91</td></tr><tr><th valign="top" colspan="4" align="center" rowspan="1">Multivariate Analysis</th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Variable</th><th valign="top" align="left" rowspan="1" colspan="1">Hazard Ratio</th><th valign="top" align="left" rowspan="1" colspan="1">95% Confidence Interval</th><th valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>-value</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age At diagnosis</td><td valign="top" align="left" rowspan="1" colspan="1">0.98</td><td valign="top" align="left" rowspan="1" colspan="1">0.97&#8211;1.1</td><td valign="top" align="left" rowspan="1" colspan="1">0.56</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Number of Neoplasms</td><td valign="top" align="left" rowspan="1" colspan="1">22.6</td><td valign="top" align="left" rowspan="1" colspan="1">1.6&#8211;324.8</td><td valign="top" align="left" rowspan="1" colspan="1">0.02</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Obesity</td><td valign="top" align="left" rowspan="1" colspan="1">0.09</td><td valign="top" align="left" rowspan="1" colspan="1">0.003&#8211;2.8</td><td valign="top" align="left" rowspan="1" colspan="1">0.18</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Smoking</td><td valign="top" align="left" rowspan="1" colspan="1">2.7</td><td valign="top" align="left" rowspan="1" colspan="1">0.3&#8211;26.9</td><td valign="top" align="left" rowspan="1" colspan="1">0.42</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Family History</td><td valign="top" align="left" rowspan="1" colspan="1">0.2</td><td valign="top" align="left" rowspan="1" colspan="1">0.1&#8211;3.2</td><td valign="top" align="left" rowspan="1" colspan="1">0.92</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Abnormal Serum Thyroglobulin</td><td valign="top" align="left" rowspan="1" colspan="1">2.5</td><td valign="top" align="left" rowspan="1" colspan="1">0.2&#8211;38.7</td><td valign="top" align="left" rowspan="1" colspan="1">0.49</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Abnormal Thyroglobulin Antibody</td><td valign="top" align="left" rowspan="1" colspan="1">1.9</td><td valign="top" align="left" rowspan="1" colspan="1">0.1&#8211;30.3</td><td valign="top" align="left" rowspan="1" colspan="1">0.63</td></tr></tbody></table></table-wrap></sec></sec></sec><sec sec-type="discussion" id="s4"><label>4</label><title>Discussion</title><p>Our research underscores an important finding regarding patients with MPN, revealing a notably lower survival rate. According to our study, MPN patients were diagnosed at an older age, displayed an elevated body mass index, and presented with increased thyroglobulin antibody levels, along with a more pronounced familial history of cancer.</p><p>The global rise in TC incidence is a widely recognized trend, largely attributed to the progress in clinical procedures, biochemical knowledge, and imaging technologies (<xref rid="B38" ref-type="bibr">38</xref>). The evolution of medical guidelines and practices, such as more thorough evaluations of the thyroid gland, has resulted in higher rates of TC detection. Progress in understanding the biochemical aspects of TC, including the identification of new biomarkers and genetic mutations linked to the disease, has also been a significant factor (<xref rid="B39" ref-type="bibr">39</xref>). Additionally, the widespread use of advanced ultrasound technology has facilitated the identification of small thyroid nodules, including thyroid microcarcinomas (<xref rid="B38" ref-type="bibr">38</xref>). In our MPN subcohort, imaging played a crucial role in the initial detection and evaluation of TC, underscoring the importance of ongoing clinical monitoring and multidisciplinary care for both cancer survivors and sufferers. However, advancements in therapeutic and diagnostic techniques have drawbacks, as previous research has linked the occurrence of secondary cancer and MPN to exposure to radiation (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>). While radiation therapy is effective in treating various types of cancer, it is also associated with an increased risk of developing additional primary malignancies. The carcinogenic impact of radiation on the thyroid gland primarily stems from the DNA damage caused by ionizing radiation, leading to genetic mutations and chromosomal abnormalities that initiate cancer formation. Additionally, exposure to radiation significantly heightens the likelihood of developing thyroid cancer, with the risk increasing in proportion to the dosage received, even at lower levels (<xref rid="B40" ref-type="bibr">40</xref>).</p><p>With regards to TC treatment, effective management strategies involve a multidisciplinary approach that incorporates surgical, oncological, medical, and radiological assessments (<xref rid="B42" ref-type="bibr">42</xref>). Surgical intervention has been found to reduce mortality and event rates in cases of operable TC, even when dealing with microcarcinomas (<xref rid="B43" ref-type="bibr">43</xref>). Furthermore, research has indicated that radioactive iodine therapy can significantly enhance survival outcomes for individuals with differentiated TC (<xref rid="B44" ref-type="bibr">44</xref>&#8211;<xref rid="B47" ref-type="bibr">47</xref>). For example, a large study involving 96,557 patients demonstrated that the use of radioactive iodine was linked to improved disease-specific survival in this population (<xref rid="B48" ref-type="bibr">48</xref>). Furthermore, radioactive iodine therapy has been shown to improve rates of recurrence-free survival, by eliminating residual thyroid tissue and microscopic disease (<xref rid="B49" ref-type="bibr">49</xref>). This treatment is particularly advantageous for patients with certain risk factors, such as extrathyroidal extension or lymph node involvement, as it reduces the likelihood of cancer recurrence (<xref rid="B50" ref-type="bibr">50</xref>).</p><p>MPN are infrequent, exhibiting a greater occurrence in older patients (<xref rid="B51" ref-type="bibr">51</xref>). The occurrence of MPN is predominantly noted in cancer survivors as well as in cancer subtypes that are associated with favorable outcomes. Therefore, the rising prevalence of TC and the favorable survival outcomes have resulted in a higher occurrence of MPN (<xref rid="B52" ref-type="bibr">52</xref>). However, MPN in survivors of TC may contribute significantly to mortality rates. This emphasizes the need for vigilant surveillance of MPN occurrence to enhance prognosis. In our study population consisting of 563 individuals, we identified 30 patients who developed MPNs, indicating a prevalence of approximately 5% at our institution, which closely aligns with prior findings from Taiwan (<xref rid="B26" ref-type="bibr">26</xref>). Lin et&#160;al. outlined that TC patients with MPN exhibit a lower female-to-male ratio, an older mean age, and more advanced TNM stages compared to those with only TC (<xref rid="B26" ref-type="bibr">26</xref>). These patients also receive higher doses of therapeutic radioactive iodine and have a higher total mortality rate (<xref rid="B26" ref-type="bibr">26</xref>). Notably, hematological malignancies and renal cell carcinoma are prevalent as secondary cancers in these patients, despite not being among the top ten common cancers in the general population of Taiwan, indicating a distinct pattern of secondary malignancies in thyroid cancer patients (<xref rid="B26" ref-type="bibr">26</xref>).</p><p>The possibility of being diagnosed with another neoplasm after surviving a first one is 14% higher for people who have previously had cancer compared to the general population (<xref rid="B53" ref-type="bibr">53</xref>). This percentage is anticipated to increase due to the growing number of cancer survivors. Consequently, there has been a rise in the occurrence of MPN among individuals who have overcome cancer, accounting for almost one-fifth of all newly diagnosed malignancies in recent studies (<xref rid="B54" ref-type="bibr">54</xref>).</p><p>With regards to MPN incidence, there is a notable variation in the reported incidence shared in current literature ranging from 1&#8211;37% (<xref rid="B55" ref-type="bibr">55</xref>). The variation observed in these findings can be attributed to the different methodologies used for calculations and the diverse ethnic populations studied. In the United States, the prevalence of primaries has been reported in percentages over time. For example, it was found to be 3.5% in New Mexico in 1977, 5.3% according to a study conducted in 1968, and finally 8% based on data from 1975&#8211;2001 (<xref rid="B56" ref-type="bibr">56</xref>&#8211;<xref rid="B58" ref-type="bibr">58</xref>). Similarly, in Western Europe, the occurrence of MPN varied across studies; it was recorded as 0.7% in a hospital registry in Scotland in 1972, 6.3% based on European cancer registries from 1995 to 1999, and reached up to 11.7% according to an autopsy series from Sweden in 1969 (<xref rid="B59" ref-type="bibr">59</xref>&#8211;<xref rid="B61" ref-type="bibr">61</xref>). The literature also shows variation in the numbers and types of multiple primaries in relation to the total number of cancer patients. For example, the incidence of three or more primaries ranged from 0.2% in a cancer center in Jordan (2006&#8211;2011) to 2.0% in a cancer center in France (1980&#8211;2009) (<xref rid="B62" ref-type="bibr">62</xref>&#8211;<xref rid="B64" ref-type="bibr">64</xref>). Similarly, metachronous primaries accounted for 3% in a recent study from the United States (2005&#8211;2012) which is equivalent to our obtained results (<xref rid="B55" ref-type="bibr">55</xref>).</p><p>Currently, there is a lack of a definitive risk factor that has been confirmed for the development of MPN. However, various factors have been previously investigated. It has been hypothesized that the presence of MPN in cancer survivors may be influenced by increased vigilance or can be a result of previous treatments, and could also be linked to mutual risk factors such as environmental factors, and genetic predisposition (<xref rid="B60" ref-type="bibr">60</xref>). In addition, ethnic background is a significant determinant of susceptibility to certain diseases (<xref rid="B55" ref-type="bibr">55</xref>). Various societies exhibit varying rates of occurrence for specific types of neoplasms (<xref rid="B14" ref-type="bibr">14</xref>). For instance, the Japanese population experiences a notable prevalence of gastric cancer, while having a relatively low incidence of prostate cancer (<xref rid="B65" ref-type="bibr">65</xref>). Conversely, the Jordanian population demonstrates a considerably higher occurrence of prostate and lung malignancies (<xref rid="B66" ref-type="bibr">66</xref>).</p><p>There is a strong correlation between obesity and the development of cancer in the general population, specifically in relation to breast cancer, genitourinary cancers, and gastrointestinal cancers (<xref rid="B67" ref-type="bibr">67</xref>). Therefore, obesity has been found to significantly increase the likelihood of developing MPN. This connection was observed in the current study, which found that patients with MPN were more likely to be obese than those with a single form of malignancy. In addition, the higher levels of baseline thyroglobulin antibodies in patients with MPN can point to the possibility of autoimmune thyroid disease. A recent cohort study by Chen et&#160;al. concluded that patients with autoimmune thyroid disease are more susceptible to developing various cancers, including breast, colorectal, and head and neck cancers (<xref rid="B68" ref-type="bibr">68</xref>). They also found that elderly patients with autoimmune thyroid disease can have an increased risk of developing thyroid and colorectal cancer compared with the general population (<xref rid="B68" ref-type="bibr">68</xref>). Therefore, clinicians must be aware of such associations in the clinical oncology care.</p><p>Family history is a significant risk factor for the development of MPN. There is a notable presence of familial clustering across almost all cancer sites, and this clustering is primarily observed in close relationships within families spanning multiple generations (<xref rid="B69" ref-type="bibr">69</xref>). The majority of hereditary cancers display an excess of multiple primary tumors and an early onset of the disease (<xref rid="B67" ref-type="bibr">67</xref>). This clustering phenomenon may be attributed to abnormal genes or gene variants. Various cancer predisposition genes, including BRCA1, BRCA2, and p16/CDKN2A, have already been identified in high-risk pedigrees (<xref rid="B67" ref-type="bibr">67</xref>, <xref rid="B69" ref-type="bibr">69</xref>). Additionally, individuals with hereditary nonpolyposis colorectal cancer who have MPN often exhibit a higher frequency of mismatch repair genes, such as hMSH2 and hMLH1 (<xref rid="B70" ref-type="bibr">70</xref>). Moreover, cribriform variants of PTC were identified as being classically linked with familial adenomatous polyposis (<xref rid="B71" ref-type="bibr">71</xref>).</p><p>Breast cancer and TC are among the most prevalent forms of cancer in women (<xref rid="B72" ref-type="bibr">72</xref>). In our study, we found a higher incidence of breast cancer in MPN patients. Breast cancer was found to be the most common secondary cancer in patients with TC, occurring either simultaneously, prior to, or after the TC diagnosis. This bidirectional relationship between thyroid and breast cancer has been previously suggested in a retrospective study, which also found an increased risk of developing a MPN in patients with a history of breast or TC (<xref rid="B73" ref-type="bibr">73</xref>). Various factors, such as iodine transport, obesity, sex hormones, thyroid hormones, and cancer treatment, have been potentially implicated in the development of both types of cancer (<xref rid="B73" ref-type="bibr">73</xref>, <xref rid="B74" ref-type="bibr">74</xref>). Lei et&#160;al. explored the prognosis of breast cancer patients who subsequently developed metachronous TC using information obtained from the Surveillance, Epidemiology, and End Results database (<xref rid="B75" ref-type="bibr">75</xref>). The study aimed to compare the prognosis of breast cancer patients who had a second primary thyroid cancer with those who did not, analyzing a wide range of clinicopathological and treatment characteristics, and evaluating the impact of second metachronous TC on breast cancer survival. The population studied included breast cancer patients diagnosed between 2000 and 2014, with a subset of these patients developing a second primary TC within this timeframe. The study found that the impact of other malignancies on TC prognosis (and vice versa) can vary depending on the type and timing of the secondary cancer, as well as the specific characteristics of the cancer itself. This study contributes significantly to understanding the complex interplay between primary and secondary malignancies, highlighting the importance of considering the type, timing, and specific characteristics of secondary cancers in the prognosis of the primary cancer (<xref rid="B75" ref-type="bibr">75</xref>).</p><p>The presentation of hematologic malignancy with a second primary neoplasm is most commonly observed during the follow-up period (<xref rid="B76" ref-type="bibr">76</xref>). Breast, lung, and TC are the most frequently occurring secondary tumors (<xref rid="B76" ref-type="bibr">76</xref>). Typically, secondary TC in these patients occurs at a later time. It has been established that radiotherapy administered at the early stages of lymphoma is linked to an increased risk of developing secondary TC (<xref rid="B77" ref-type="bibr">77</xref>). Another study demonstrated that prior radiotherapy of the head, neck, and upper diaphragm may also contribute to the development of TC (<xref rid="B78" ref-type="bibr">78</xref>). In lymphoma patients, a recent study found that diffuse large B-cell lymphoma was the most commonly observed hematologic malignancy alongside TC in MPN patients (<xref rid="B76" ref-type="bibr">76</xref>). Similar to our findings, PTC was the most coinciding malignancy discovered incidentally (<xref rid="B76" ref-type="bibr">76</xref>).</p><p>Based on our analysis, it was found that patients with MPN exhibited a lower survival rate. This is more in line with previous research findings, as MPN had shown a detrimental and statistically significant impact on the survival of patients with TC (<xref rid="B52" ref-type="bibr">52</xref>). Liou et&#160;al. found that the overall mortality rate in TC patients with MPN could be 4.4 times higher compared to those without MPN (<xref rid="B79" ref-type="bibr">79</xref>). Similarly, Lang et&#160;al. reported a considerable mortality rate of 43.5% in TC patients with nonsynchronous MPN (<xref rid="B80" ref-type="bibr">80</xref>).</p><p>This study faces several limitations, chiefly due to its retrospective nature, a limited number of patients, and being conducted at a single institution. Moreover, despite attempts to mitigate confounding variables through propensity score matching and the exclusion of genetic conditions, the retrospective approach may have compromised accurate final selection due to the lack of exhaustive details on genetic testing, thyroid marker assays, and laboratory analyses, among other factors. Despite this, the present study is the first to address this topic using propensity score-matching among MPN patients of Middle-Eastern ethnicity.</p></sec><sec sec-type="conclusions" id="s5"><label>5</label><title>Conclusion</title><p>The onset of MPN can significantly influence the survival outcome of TC patients. The diagnosis of thyroid carcinoma at an older age, accompanied by elevated initial thyroglobulin antibody levels and a notable familial predisposition, may raise concerns about the potential occurrence of synchronous or metachronous neoplastic manifestations. Further analysis with larger patient cohorts is necessary to confirm the results of this study.</p></sec><sec sec-type="data-availability" id="s6"><title>Data availability statement</title><p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p></sec><sec sec-type="ethics-statement" id="s7"><title>Ethics statement</title><p>The studies involving humans were approved by Institutional Review Board of King Hussein Cancer Center (KHCC) in Amman, Jordan (Registration number: 22 KHCC 131, 11 August 2022). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.</p></sec><sec sec-type="author-contributions" id="s8"><title>Author contributions</title><p>A-AI: Conceptualization, Data curation, Formal Analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing &#8211; original draft, Writing &#8211; review &amp; editing. ASA: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Software, Writing &#8211; original draft, Writing &#8211; review &amp; editing. DA-A: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Project administration, Writing &#8211; original draft, Writing &#8211; review &amp; editing. EL: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Project administration, Software, Supervision, Writing &#8211; original draft, Writing &#8211; review &amp; editing. AA-O: Conceptualization, Writing &#8211; original draft, Writing &#8211; review &amp; editing. MA-M: Conceptualization, Investigation, Writing &#8211; original draft, Writing &#8211; review &amp; editing. YY: Conceptualization, Data curation, Formal Analysis, Writing &#8211; original draft, Writing &#8211; review &amp; editing. NA-H: Writing &#8211; original draft, Writing &#8211; review &amp; editing. IM: Writing &#8211; original draft, Writing &#8211; review &amp; editing. SS: Writing &#8211; review &amp; editing, Methodology, Writing &#8211; original draft. GS: Conceptualization, Formal Analysis, Methodology, Validation, Writing &#8211; original draft, Writing &#8211; review &amp; editing.</p></sec></body><back><sec sec-type="COI-statement" id="s10"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p><p>The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</p></sec><sec sec-type="disclaimer" id="s11"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pettersson</surname><given-names>B</given-names></name><name name-style="western"><surname>Adami</surname><given-names>HO</given-names></name><name name-style="western"><surname>Wilander</surname><given-names>E</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>MP</given-names></name></person-group>. <article-title>Trends in thyroid cancer incidence in Sweden, 1958&#8211;1981, by histopathologic type</article-title>. <source>Int J Cancer</source>. (<year>1991</year>) <volume>48</volume>:<fpage>28</fpage>&#8211;<lpage>33</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1002/ijc.2910480106</pub-id><pub-id pub-id-type="pmid">2019455</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>dos Santos Silva</surname><given-names>I</given-names></name><name name-style="western"><surname>Swerdlow</surname><given-names>A</given-names></name></person-group>. <article-title>Thyroid cancer epidemiology in England and Wales: time trends and geographical distribution</article-title>. <source>Br J Cancer</source>. (<year>1993</year>) <volume>67</volume>:<page-range>330&#8211;40</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/bjc.1993.61</pub-id><pub-id pub-id-type="pmcid">PMC1968194</pub-id><pub-id pub-id-type="pmid">8431362</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haselkorn</surname><given-names>T</given-names></name><name name-style="western"><surname>Bernstein</surname><given-names>L</given-names></name><name name-style="western"><surname>Preston-Martin</surname><given-names>S</given-names></name><name name-style="western"><surname>Cozen</surname><given-names>W</given-names></name><name name-style="western"><surname>Mack</surname><given-names>WJ</given-names></name></person-group>. <article-title>Descriptive epidemiology of thyroid cancer in Los Angeles County, 1972&#8211;1995</article-title>. <source>Cancer Causes Control</source>. (<year>2000</year>) <volume>11</volume>:<page-range>163&#8211;70</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1023/A:1008932123830</pub-id><pub-id pub-id-type="pmid">10710201</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burgess</surname><given-names>JR</given-names></name></person-group>. <article-title>Temporal trends for thyroid carcinoma in Australia: an increasing incidence of papillary thyroid carcinoma (1982&#8211;1997)</article-title>. <source>Thyroid</source>. (<year>2002</year>) <volume>12</volume>:<page-range>141&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1089/105072502753522374</pub-id><pub-id pub-id-type="pmid">11916283</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reynolds</surname><given-names>RM</given-names></name><name name-style="western"><surname>Weir</surname><given-names>J</given-names></name><name name-style="western"><surname>Stockton</surname><given-names>DL</given-names></name><name name-style="western"><surname>Brewster</surname><given-names>DH</given-names></name><name name-style="western"><surname>Sandeep</surname><given-names>TC</given-names></name><name name-style="western"><surname>Strachan</surname><given-names>MW</given-names></name></person-group>. <article-title>Changing trends in incidence and mortality of thyroid cancer in Scotland</article-title>. <source>Clin Endocrinol (Oxf)</source>. (<year>2005</year>) <volume>62</volume>:<page-range>156&#8211;62</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1365-2265.2004.02187.x</pub-id><pub-id pub-id-type="pmid">15670190</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>L</given-names></name><name name-style="western"><surname>Welch</surname><given-names>HG</given-names></name></person-group>. <article-title>Increasing incidence of thyroid cancer in the United States, 1973&#8211;2002</article-title>. <source>JAMA</source>. (<year>2006</year>) <volume>295</volume>:<page-range>2164&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1001/jama.295.18.2164</pub-id><pub-id pub-id-type="pmid">16684987</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayat</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Howlader</surname><given-names>N</given-names></name><name name-style="western"><surname>Reichman</surname><given-names>ME</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>BK</given-names></name></person-group>. <article-title>Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program</article-title>. <source>oncologist</source>. (<year>2007</year>) <volume>12</volume>:<fpage>20</fpage>&#8211;<lpage>37</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1634/theoncologist.12-1-20</pub-id><pub-id pub-id-type="pmid">17227898</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verkooijen</surname><given-names>HM</given-names></name><name name-style="western"><surname>Fioretta</surname><given-names>G</given-names></name><name name-style="western"><surname>Pache</surname><given-names>J-C</given-names></name><name name-style="western"><surname>Franceschi</surname><given-names>S</given-names></name><name name-style="western"><surname>Raymond</surname><given-names>L</given-names></name><name name-style="western"><surname>Schubert</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Diagnostic changes as a reason for the increase in papillary thyroid cancer incidence in Geneva, Switzerland</article-title>. <source>Cancer Causes Control</source>. (<year>2003</year>) <volume>14</volume>:<page-range>13&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1023/A:1022593923603</pub-id><pub-id pub-id-type="pmid">12708720</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vecchia</surname><given-names>CL</given-names></name><name name-style="western"><surname>Ron</surname><given-names>E</given-names></name><name name-style="western"><surname>Franceschi</surname><given-names>S</given-names></name><name name-style="western"><surname>Maso</surname><given-names>LD</given-names></name><name name-style="western"><surname>Mark</surname><given-names>SD</given-names></name><name name-style="western"><surname>Chatenoud</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>A pooled analysis of case-control studies of thyroid cancer. III. Oral contraceptives, menopausal replacement therapy and other female hormones</article-title>. <source>Cancer Causes Control</source>. (<year>1999</year>) <volume>10</volume>:<page-range>157&#8211;66</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1023/A:1008832513932</pub-id><pub-id pub-id-type="pmid">10231164</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hemminki</surname><given-names>K</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name></person-group>. <article-title>Gender effects in familial cancer</article-title>. <source>Int J Cancer</source>. (<year>2002</year>) <volume>102</volume>:<page-range>184&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/ijc.10676</pub-id><pub-id pub-id-type="pmid">12385016</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sherman</surname><given-names>SI</given-names></name><name name-style="western"><surname>Perrier</surname><given-names>N</given-names></name><name name-style="western"><surname>Clayman</surname><given-names>GL</given-names></name></person-group>. <article-title>Thyroid Cancer</article-title>. <source>Springer</source>. (<year>2012</year>), <fpage>295</fpage>&#8211;<lpage>310</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/978-1-4614-5197-6_26</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sant</surname><given-names>M</given-names></name><name name-style="western"><surname>Aareleid</surname><given-names>T</given-names></name><name name-style="western"><surname>Berrino</surname><given-names>F</given-names></name><name name-style="western"><surname>Lasota</surname><given-names>MB</given-names></name><name name-style="western"><surname>Carli</surname><given-names>P</given-names></name><name name-style="western"><surname>Faivre</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>EUROCARE-3: survival of cancer patients diagnosed 1990&#8211;94&#8212;results and commentary</article-title>. <source>Ann Oncol</source>. (<year>2003</year>) <volume>14</volume>:<fpage>v61</fpage>&#8211;<lpage>v118</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1093/annonc/mdg754</pub-id><pub-id pub-id-type="pmid">14684501</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gilliland</surname><given-names>FD</given-names></name><name name-style="western"><surname>Hunt</surname><given-names>WC</given-names></name><name name-style="western"><surname>Morris</surname><given-names>DM</given-names></name><name name-style="western"><surname>Key</surname><given-names>CR</given-names></name></person-group>. <article-title>Prognostic factors for thyroid carcinoma: A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) Program 1973&#8211;1991</article-title>. <source>Cancer: Interdiscip Int J Am Cancer Society</source>. (<year>1997</year>) <volume>79</volume>:<page-range>564&#8211;73</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/(ISSN)1097-0142</pub-id><pub-id pub-id-type="pmid">9028369</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Ibraheem</surname><given-names>A</given-names></name><name name-style="western"><surname>Al-Rasheed</surname><given-names>U</given-names></name><name name-style="western"><surname>Mashhadani</surname><given-names>N</given-names></name><name name-style="western"><surname>Abdlkadir</surname><given-names>AS</given-names></name><name name-style="western"><surname>Al-Adhami</surname><given-names>DA</given-names></name><name name-style="western"><surname>Ruzzeh</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Long-term survival analysis and prognostic factors of arabic patients with differentiated thyroid carcinoma: A 20-year observational study at the King Hussein Cancer Center (KHCC) involving 528 patients</article-title>. <source>Cancers (Basel)</source>. (<year>2023</year>) <volume>15</volume>:<fpage>4102</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.3390/cancers15164102</pub-id><pub-id pub-id-type="pmid">37627130</pub-id><pub-id pub-id-type="pmcid">PMC10452119</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baloch</surname><given-names>ZW</given-names></name><name name-style="western"><surname>Asa</surname><given-names>SL</given-names></name><name name-style="western"><surname>Barletta</surname><given-names>JA</given-names></name><name name-style="western"><surname>Ghossein</surname><given-names>RA</given-names></name><name name-style="western"><surname>Juhlin</surname><given-names>CC</given-names></name><name name-style="western"><surname>Jung</surname><given-names>CK</given-names></name><etal/></person-group>. <article-title>Overview of the 2022 WHO classification of thyroid neoplasms</article-title>. <source>Endocr Pathol</source>. (<year>2022</year>) <volume>33</volume>:<fpage>27</fpage>&#8211;<lpage>63</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s12022-022-09707-3</pub-id><pub-id pub-id-type="pmid">35288841</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pstr&#261;g</surname><given-names>N</given-names></name><name name-style="western"><surname>Ziemnicka</surname><given-names>K</given-names></name><name name-style="western"><surname>Bluyssen</surname><given-names>H</given-names></name><name name-style="western"><surname>Weso&#322;y</surname><given-names>J</given-names></name></person-group>. <article-title>Thyroid cancers of follicular origin in a genomic light: in-depth overview of common and unique molecular marker candidates</article-title>. <source>Mol Cancer</source>. (<year>2018</year>) <volume>17</volume>:<fpage>1</fpage>&#8211;<lpage>17</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12943-018-0866-1</pub-id><pub-id pub-id-type="pmid">30089490</pub-id><pub-id pub-id-type="pmcid">PMC6081953</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rossi</surname><given-names>ED</given-names></name><name name-style="western"><surname>Pantanowitz</surname><given-names>L</given-names></name><name name-style="western"><surname>Hornick</surname><given-names>JL</given-names></name></person-group>. <article-title>A worldwide journey of thyroid cancer incidence centered on tumor histology</article-title>. <source>Lancet Diabetes Endocrinol</source>. (<year>2021</year>) <volume>9</volume>:<page-range>193&#8211;4</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S2213-8587(21)00049-8</pub-id><pub-id pub-id-type="pmid">33662332</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Che</surname><given-names>W</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>S</given-names></name><name name-style="western"><surname>Xie</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>The incidence trend of papillary thyroid carcinoma in the United States during 2003&#8211;2017</article-title>. <source>Cancer Control</source>. (<year>2022</year>) <volume>29</volume>:<fpage>10732748221135447</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1177/10732748221135447</pub-id><pub-id pub-id-type="pmid">36256588</pub-id><pub-id pub-id-type="pmcid">PMC9583193</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ulisse</surname><given-names>S</given-names></name><name name-style="western"><surname>Baldini</surname><given-names>E</given-names></name><name name-style="western"><surname>Lauro</surname><given-names>A</given-names></name><name name-style="western"><surname>Pironi</surname><given-names>D</given-names></name><name name-style="western"><surname>Tripodi</surname><given-names>D</given-names></name><name name-style="western"><surname>Lori</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Papillary thyroid cancer prognosis: An evolving field</article-title>. <source>Cancers (Basel)</source>. (<year>2021</year>) <volume>13</volume>:<fpage>5567</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.3390/cancers13215567</pub-id><pub-id pub-id-type="pmid">34771729</pub-id><pub-id pub-id-type="pmcid">PMC8582937</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Badulescu</surname><given-names>C</given-names></name><name name-style="western"><surname>Piciu</surname><given-names>D</given-names></name><name name-style="western"><surname>Apostu</surname><given-names>D</given-names></name><name name-style="western"><surname>Badan</surname><given-names>M</given-names></name><name name-style="western"><surname>Piciu</surname><given-names>A</given-names></name></person-group>. <article-title>Follicular thyroid carcinoma-clinical and diagnostic findings in a 20-year follow up study</article-title>. <source>Acta Endocrinologica (Bucharest)</source>. (<year>2020</year>) <volume>50</volume>:<fpage>170</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.4183/aeb.2020.170</pub-id><pub-id pub-id-type="pmcid">PMC7535902</pub-id><pub-id pub-id-type="pmid">33029233</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagaiah</surname><given-names>G</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>A</given-names></name><name name-style="western"><surname>Mooney</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Parmentier</surname><given-names>J</given-names></name><name name-style="western"><surname>Remick</surname><given-names>SC</given-names></name></person-group>. <article-title>Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment</article-title>. <source>J Oncol</source>. (<year>2011</year>) <volume>2011</volume>: <page-range>1&#8211;13</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1155/2011/542358</pub-id><pub-id pub-id-type="pmcid">PMC3136148</pub-id><pub-id pub-id-type="pmid">21772843</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Ibraheem</surname><given-names>A</given-names></name><name name-style="western"><surname>Alyasjeen</surname><given-names>SF</given-names></name><name name-style="western"><surname>Abdlkadir</surname><given-names>AS</given-names></name><name name-style="western"><surname>Sheikha</surname><given-names>AA</given-names></name></person-group>. <article-title>[68Ga] Ga-DOTA-FAPI-04 PET/CT depicts metastases from medullary thyroid cancer that [68Ga] Ga-DOTATOC PET/CT missed</article-title>. <source>Eur J Nucl Med Mol Imaging</source>. (<year>2023</year>), <fpage>1</fpage>&#8211;<lpage>2</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00259-023-06348-4</pub-id><pub-id pub-id-type="pmid">37490080</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sandeep</surname><given-names>TC</given-names></name><name name-style="western"><surname>Strachan</surname><given-names>MW</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>RM</given-names></name><name name-style="western"><surname>Brewster</surname><given-names>DH</given-names></name><name name-style="western"><surname>Sc&#233;lo</surname><given-names>G</given-names></name><name name-style="western"><surname>Pukkala</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Second primary cancers in thyroid cancer patients: a multinational record linkage study</article-title>. <source>J Clin Endocrinol Metab</source>. (<year>2006</year>) <volume>91</volume>:<page-range>1819&#8211;25</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1210/jc.2005-2009</pub-id><pub-id pub-id-type="pmid">16478820</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rubino</surname><given-names>C</given-names></name><name name-style="western"><surname>De Vathaire</surname><given-names>F</given-names></name><name name-style="western"><surname>Dottorini</surname><given-names>M</given-names></name><name name-style="western"><surname>Hall</surname><given-names>P</given-names></name><name name-style="western"><surname>Schvartz</surname><given-names>C</given-names></name><name name-style="western"><surname>Couette</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Second primary Malignancies in thyroid cancer patients</article-title>. <source>Br J Cancer</source>. (<year>2003</year>) <volume>89</volume>:<page-range>1638&#8211;44</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/sj.bjc.6601319</pub-id><pub-id pub-id-type="pmcid">PMC2394426</pub-id><pub-id pub-id-type="pmid">14583762</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ronckers</surname><given-names>CM</given-names></name><name name-style="western"><surname>McCarron</surname><given-names>P</given-names></name><name name-style="western"><surname>Ron</surname><given-names>E</given-names></name></person-group>. <article-title>Thyroid cancer and multiple primary tumors in the SEER cancer registries 1</article-title>. <source>Int J Cancer</source>. (<year>2005</year>) <volume>117</volume>:<page-range>281&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/ijc.21064</pub-id><pub-id pub-id-type="pmid">15880372</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>J</given-names></name><name name-style="western"><surname>Lin</surname><given-names>K</given-names></name><name name-style="western"><surname>Chao</surname><given-names>T</given-names></name><name name-style="western"><surname>Hseuh</surname><given-names>C</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>N</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B</given-names></name></person-group>. <article-title>Clinical presentations of thyroid cancer patients with multiple primary cancers</article-title>. <source>J Endocrinological Invest</source>. (<year>2011</year>) <volume>34</volume>:<page-range>824&#8211;30</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.3275/7747</pub-id><pub-id pub-id-type="pmid">21613811</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adjadj</surname><given-names>&#201;</given-names></name><name name-style="western"><surname>Rubino</surname><given-names>C</given-names></name><name name-style="western"><surname>Shamsaldim</surname><given-names>A</given-names></name><name name-style="western"><surname>L&#234;</surname><given-names>MG</given-names></name><name name-style="western"><surname>Schlumberger</surname><given-names>M</given-names></name><name name-style="western"><surname>de Vathaire</surname><given-names>F</given-names></name></person-group>. <article-title>The risk of multiple primary breast and thyroid carcinomas: Role of the radiation dose</article-title>. <source>Cancer: Interdiscip Int J Am Cancer Society</source>. (<year>2003</year>) <volume>98</volume>:<page-range>1309&#8211;17</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/cncr.11626</pub-id><pub-id pub-id-type="pmid">12973856</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oemuer</surname><given-names>O</given-names></name><name name-style="western"><surname>Oezcan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yazici</surname><given-names>B</given-names></name><name name-style="western"><surname>Akg&#252;n</surname><given-names>A</given-names></name><name name-style="western"><surname>Oral</surname><given-names>A</given-names></name><name name-style="western"><surname>Oezkilic</surname><given-names>H</given-names></name></person-group>. <article-title>Multiple primary tumors in differentiated thyroid carcinoma and relationship to thyroid cancer outcome</article-title>. <source>Endocr J</source>. (<year>2008</year>) <volume>55</volume>:<page-range>365&#8211;72</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1507/endocrj.K07E-058</pub-id><pub-id pub-id-type="pmid">18277003</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tucker</surname><given-names>M</given-names></name><name name-style="western"><surname>Boice</surname><given-names>J</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Hoffman</surname><given-names>D</given-names></name></person-group>. <article-title>Second cancer following cutaneous melanoma and cancers of the brain, thyroid, connective tissue, bone, and eye in Connecticut, 1935&#8211;82</article-title>. <source>Natl Cancer Institute Monograph</source>. (<year>1985</year>) <volume>68</volume>:<page-range>161&#8211;89</page-range>.<pub-id pub-id-type="pmid">4088297</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osterlind</surname><given-names>A</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>JH</given-names></name><name name-style="western"><surname>Lynge</surname><given-names>E</given-names></name><name name-style="western"><surname>Ewertz</surname><given-names>M</given-names></name></person-group>. <article-title>Second cancer following cutaneous melanoma and cancers of the brain, thyroid, connective tissue, bone, and eye in Denmark, 1943&#8211;80</article-title>. <source>Natl Cancer Institute Monograph</source>. (<year>1985</year>) <volume>68</volume>:<page-range>361&#8211;88</page-range>.<pub-id pub-id-type="pmid">4088310</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teppo</surname><given-names>L</given-names></name><name name-style="western"><surname>Pukkala</surname><given-names>E</given-names></name><name name-style="western"><surname>Sax&#233;n</surname><given-names>E</given-names></name></person-group>. <article-title>Multiple cancer&#8212;an epidemiologic exercise in Finland</article-title>. <source>J Natl Cancer Inst</source>. (<year>1985</year>) <volume>75</volume>:<page-range>207&#8211;17</page-range>.<pub-id pub-id-type="pmid">3860679</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levi</surname><given-names>F</given-names></name><name name-style="western"><surname>Randimbison</surname><given-names>L</given-names></name><name name-style="western"><surname>Te</surname><given-names>V</given-names></name><name name-style="western"><surname>Rolland-Portal</surname><given-names>I</given-names></name><name name-style="western"><surname>Franceschi</surname><given-names>S</given-names></name><name name-style="western"><surname>La Vecchia</surname><given-names>C</given-names></name></person-group>. <article-title>Multiple primary cancers in the Vaud Cancer registry, Switzerland, 1974&#8211;89</article-title>. <source>Br J Cancer</source>. (<year>1993</year>) <volume>67</volume>:<page-range>391&#8211;5</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/bjc.1993.72</pub-id><pub-id pub-id-type="pmcid">PMC1968177</pub-id><pub-id pub-id-type="pmid">8431373</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Amin</surname><given-names>MB</given-names></name><name name-style="western"><surname>Edge</surname><given-names>SB</given-names></name><name name-style="western"><surname>Greene</surname><given-names>FL</given-names></name><name name-style="western"><surname>Byrd</surname><given-names>DR</given-names></name><name name-style="western"><surname>Brookland</surname><given-names>RK</given-names></name><name name-style="western"><surname>Washington</surname><given-names>MK</given-names></name><etal/></person-group>. <source>AJCC cancer staging manual</source> Vol. <volume>1024</volume>. <publisher-loc>New Jersey, United States</publisher-loc>: <publisher-name>Springer</publisher-name> (<year>2017</year>).</mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Ren</surname><given-names>C</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ye</surname><given-names>F</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>The role of thyroglobulin in preoperative and postoperative evaluation of patients with differentiated thyroid cancer</article-title>. <source>Front Endocrinol (Lausanne)</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>872527</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fendo.2022.872527</pub-id><pub-id pub-id-type="pmid">35721746</pub-id><pub-id pub-id-type="pmcid">PMC9200986</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warren</surname><given-names>S</given-names></name><name name-style="western"><surname>Gates</surname><given-names>O</given-names></name></person-group>. <article-title>A survey of the literature and statistical study</article-title>. <source>Am J Cancer</source>. (<year>1932</year>) <volume>16</volume>:<fpage>1358</fpage>&#8211;<lpage>4142</lpage>.</mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coyte</surname><given-names>A</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>DS</given-names></name><name name-style="western"><surname>McLoone</surname><given-names>P</given-names></name></person-group>. <article-title>Second primary cancer risk-the impact of applying different definitions of multiple primaries: results from a retrospective population-based cancer registry study</article-title>. <source>BMC Cancer</source>. (<year>2014</year>) <volume>14</volume>:<fpage>1</fpage>&#8211;<lpage>11</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/1471-2407-14-272</pub-id><pub-id pub-id-type="pmid">24742063</pub-id><pub-id pub-id-type="pmcid">PMC4005906</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nos&#233;</surname><given-names>V</given-names></name></person-group>. <article-title>Familial thyroid cancer: a review</article-title>. <source>Mod Pathol</source>. (<year>2011</year>) <volume>24</volume>:<page-range>S19&#8211;33</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/modpathol.2010.147</pub-id><pub-id pub-id-type="pmid">21455198</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>H</given-names></name><name name-style="western"><surname>Devesa</surname><given-names>SS</given-names></name><name name-style="western"><surname>Sosa</surname><given-names>JA</given-names></name><name name-style="western"><surname>Check</surname><given-names>D</given-names></name><name name-style="western"><surname>Kitahara</surname><given-names>CM</given-names></name></person-group>. <article-title>Trends in thyroid cancer incidence and mortality in the United States, 1974&#8211;2013</article-title>. <source>JAMA</source>. (<year>2017</year>) <volume>317</volume>:<page-range>1338&#8211;48</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1001/jama.2017.2719</pub-id><pub-id pub-id-type="pmcid">PMC8216772</pub-id><pub-id pub-id-type="pmid">28362912</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grogan</surname><given-names>RH</given-names></name><name name-style="western"><surname>Mitmaker</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Clark</surname><given-names>OH</given-names></name></person-group>. <article-title>The evolution of biomarkers in thyroid cancer&#8212;From mass screening to a personalized biosignature</article-title>. <source>Cancers (Basel)</source>. (<year>2010</year>) <volume>2</volume>:<fpage>885</fpage>&#8211;<lpage>912</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.3390/cancers2020885</pub-id><pub-id pub-id-type="pmid">24281099</pub-id><pub-id pub-id-type="pmcid">PMC3835110</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iglesias</surname><given-names>ML</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>A</given-names></name><name name-style="western"><surname>Ghuzlan</surname><given-names>AA</given-names></name><name name-style="western"><surname>Lacroix</surname><given-names>L</given-names></name><name name-style="western"><surname>Vathaire</surname><given-names>F</given-names></name><name name-style="western"><surname>Chevillard</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Radiation exposure and thyroid cancer: a review</article-title>. <source>Arch Endocrinol Metab</source>. (<year>2017</year>) <volume>61</volume>:<page-range>180&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1590/2359-3997000000257</pub-id><pub-id pub-id-type="pmcid">PMC10118869</pub-id><pub-id pub-id-type="pmid">28225863</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>AP</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Hitchcock</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Szabo</surname><given-names>A</given-names></name><name name-style="western"><surname>Shrieve</surname><given-names>DC</given-names></name><name name-style="western"><surname>Tward</surname><given-names>JD</given-names></name></person-group>. <article-title>The Risk of Second Primary Malignancies up to Three Decades after the Treatment of Differentiated Thyroid Cancer</article-title>. <source>J Clin Endocrinol Metab</source>. (<year>2008</year>) <volume>93</volume>:<page-range>504&#8211;15</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1210/jc.2007-1154</pub-id><pub-id pub-id-type="pmid">18029468</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Mallick</surname><given-names>UK</given-names></name><name name-style="western"><surname>Harmer</surname><given-names>C</given-names></name></person-group>. <source>Practical management of thyroid cancer: A multidisciplinary approach</source>. <publisher-loc>Berlin, Germany</publisher-loc>: <publisher-name>Springer</publisher-name> (<year>2018</year>). doi:&#160;<pub-id pub-id-type="doi">10.1007/978-3-319-91725-2</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bi</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name></person-group>. <article-title>A meta-analysis of total thyroidectomy and lobectomy outcomes in papillary thyroid microcarcinoma</article-title>. <source>Medicine</source>. (<year>2023</year>) <volume>102</volume>. doi:&#160;<pub-id pub-id-type="doi">10.1097/MD.0000000000036647</pub-id><pub-id pub-id-type="pmcid">PMC10727648</pub-id><pub-id pub-id-type="pmid">38115346</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S</given-names></name></person-group>. <article-title>Radioactive iodine therapy in patients with thyroid carcinoma with distant metastases: a SEER-based study</article-title>. <source>Cancer Control</source>. (<year>2020</year>) <volume>27</volume>:<fpage>1073274820914661</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1177/1073274820914661</pub-id><pub-id pub-id-type="pmid">32292051</pub-id><pub-id pub-id-type="pmcid">PMC7160783</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>J</given-names></name><name name-style="western"><surname>Kong</surname><given-names>D</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><name name-style="western"><surname>Liao</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>The role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on SEER</article-title>. <source>Onco Targets Ther</source>. (<year>2018</year>) <volume>11</volume>:<page-range>3551&#8211;60</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.2147/OTT</pub-id><pub-id pub-id-type="pmcid">PMC6016280</pub-id><pub-id pub-id-type="pmid">29950860</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chai</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Q</given-names></name><name name-style="western"><surname>Tan</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Predictive value of clinical and pathological characteristics for metastatic radioactive iodine-refractory differentiated thyroid carcinoma: a 16-year retrospective study</article-title>. <source>Front Endocrinol (Lausanne)</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>930180</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fendo.2022.930180</pub-id><pub-id pub-id-type="pmid">35846335</pub-id><pub-id pub-id-type="pmcid">PMC9281388</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Ibraheem</surname><given-names>A</given-names></name><name name-style="western"><surname>Al-Shammaa</surname><given-names>M</given-names></name><name name-style="western"><surname>Abdlkadir</surname><given-names>AS</given-names></name><name name-style="western"><surname>Istatieh</surname><given-names>F</given-names></name><name name-style="western"><surname>Al-Rasheed</surname><given-names>U</given-names></name><name name-style="western"><surname>Pascual</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Survival trends in pediatric differentiated thyroid cancer: A middle eastern perspective</article-title>. <source>Life</source>. (<year>2024</year>) <volume>14</volume>:<fpage>158</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.3390/life14010158</pub-id><pub-id pub-id-type="pmid">38276287</pub-id><pub-id pub-id-type="pmcid">PMC10820815</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alshwayyat</surname><given-names>SA</given-names></name><name name-style="western"><surname>Al-Akhras</surname><given-names>A</given-names></name><name name-style="western"><surname>Ababneh</surname><given-names>OE</given-names></name><name name-style="western"><surname>Alshwayyat</surname><given-names>TA</given-names></name><name name-style="western"><surname>Ghazou</surname><given-names>A</given-names></name></person-group>. <article-title>The effect of radioactive iodine (RAI) on disease-specific survival in differentiated thyroid cancer (DTC): A study of 96,557 patients</article-title>. <source>J Clin Oncol</source>. (<year>2023</year>) <volume>41</volume>:<page-range>e18095&#8211;5</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1200/JCO.2023.41.16_suppl.e18095</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iizuka</surname><given-names>Y</given-names></name><name name-style="western"><surname>Katagiri</surname><given-names>T</given-names></name><name name-style="western"><surname>Ogura</surname><given-names>K</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>M</given-names></name><name name-style="western"><surname>Nakashima</surname><given-names>R</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Recurrence-free survival and prognosis after adjuvant therapy with radioactive iodine-131 in patients with differentiated thyroid carcinoma</article-title>. <source>Sci Rep</source>. (<year>2023</year>) <volume>13</volume>:<fpage>10795</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41598-023-37899-z</pub-id><pub-id pub-id-type="pmid">37402838</pub-id><pub-id pub-id-type="pmcid">PMC10319734</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>He</surname><given-names>X</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Tan</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>The impact of radioactive iodine treatment on survival among papillary thyroid cancer patients according to the 7th and 8th editions of the AJCC/TNM staging system: a SEER-based study</article-title>. <source>Updates Surg</source>. (<year>2020</year>) <volume>72</volume>:<page-range>871&#8211;84</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s13304-020-00773-y</pub-id><pub-id pub-id-type="pmid">32342347</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Demandante</surname><given-names>CGN</given-names></name><name name-style="western"><surname>Troyer</surname><given-names>DA</given-names></name><name name-style="western"><surname>Miles</surname><given-names>TP</given-names></name></person-group>. <article-title>Multiple primary Malignant neoplasms: case report and a comprehensive review of the literature</article-title>. <source>Am J Clin Oncol</source>. (<year>2003</year>) <volume>26</volume>:<fpage>79</fpage>&#8211;<lpage>83</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1097/00000421-200302000-00015</pub-id><pub-id pub-id-type="pmid">12576929</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>ST</given-names></name><name name-style="western"><surname>Chi</surname><given-names>SY</given-names></name><name name-style="western"><surname>Wang</surname><given-names>PW</given-names></name><name name-style="western"><surname>Chen</surname><given-names>YN</given-names></name><name name-style="western"><surname>Yang</surname><given-names>YT</given-names></name><name name-style="western"><surname>Chen</surname><given-names>WC</given-names></name><etal/></person-group>. <article-title>Analysis of overall survival in differentiated thyroid cancer patients with double primary Malignancy</article-title>. <source>Kaohsiung J Med Sci</source>. (<year>2021</year>) <volume>37</volume>:<fpage>63</fpage>&#8211;<lpage>71</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1002/kjm2.12286</pub-id><pub-id pub-id-type="pmid">32841516</pub-id><pub-id pub-id-type="pmcid">PMC11896261</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>E</given-names></name><name name-style="western"><surname>Louwman</surname><given-names>M</given-names></name><name name-style="western"><surname>Aben</surname><given-names>K</given-names></name><name name-style="western"><surname>Janssen-Heijnen</surname><given-names>M</given-names></name><name name-style="western"><surname>Brink</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Prevalence of multiple Malignancies in the Netherlands in 2007</article-title>. <source>Int J Cancer</source>. (<year>2011</year>) <volume>128</volume>:<page-range>1659&#8211;67</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/ijc.25480</pub-id><pub-id pub-id-type="pmid">20503267</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Travis</surname><given-names>LB</given-names></name><name name-style="western"><surname>Rabkin</surname><given-names>CS</given-names></name><name name-style="western"><surname>Brown</surname><given-names>LM</given-names></name><name name-style="western"><surname>Allan</surname><given-names>JM</given-names></name><name name-style="western"><surname>Alter</surname><given-names>BP</given-names></name><name name-style="western"><surname>Ambrosone</surname><given-names>CB</given-names></name><etal/></person-group>. <article-title>Cancer survivorship&#8212;genetic susceptibility and second primary cancers: research strategies and recommendations</article-title>. <source>J Natl Cancer Inst</source>. (<year>2006</year>) <volume>98</volume>:<fpage>15</fpage>&#8211;<lpage>25</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1093/jnci/djj001</pub-id><pub-id pub-id-type="pmid">16391368</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amer</surname><given-names>MH</given-names></name></person-group>. <article-title>Multiple neoplasms, single primaries, and patient survival</article-title>. <source>Cancer Manag Res</source>. (<year>2014</year>) <volume>6</volume>:<page-range>119&#8211;34</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.2147/CMAR</pub-id><pub-id pub-id-type="pmcid">PMC3949559</pub-id><pub-id pub-id-type="pmid">24623992</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mariotto</surname><given-names>AB</given-names></name><name name-style="western"><surname>Rowland</surname><given-names>JH</given-names></name><name name-style="western"><surname>Ries</surname><given-names>LA</given-names></name><name name-style="western"><surname>Scoppa</surname><given-names>S</given-names></name><name name-style="western"><surname>Feuer</surname><given-names>EJ</given-names></name></person-group>. <article-title>Multiple cancer prevalence: a growing challenge in long-term survivorship</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source>. (<year>2007</year>) <volume>16</volume>:<page-range>566&#8211;71</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1158/1055-9965.EPI-06-0782</pub-id><pub-id pub-id-type="pmid">17372253</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bordin</surname><given-names>GM</given-names></name><name name-style="western"><surname>Key</surname><given-names>CR</given-names></name><name name-style="western"><surname>McQuade</surname><given-names>CE</given-names></name><name name-style="western"><surname>Kutvirt</surname><given-names>DM</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>WB</given-names></name><name name-style="western"><surname>Brylinski</surname><given-names>DA</given-names></name></person-group>. <article-title>Multiple primary cancers. Relative risk in New Mexico&#8217;s triethnic population</article-title>. <source>Cancer</source>. (<year>1977</year>) <volume>40</volume>:<page-range>1793&#8211;800</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/(ISSN)1097-0142</pub-id><pub-id pub-id-type="pmid">907983</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hajdu</surname><given-names>SI</given-names></name><name name-style="western"><surname>Hajdu</surname><given-names>EO</given-names></name></person-group>. <article-title>Multiple primary Malignant tumors</article-title>. <source>J Am Geriatr Soc</source>. (<year>1968</year>) <volume>16</volume>:<fpage>16</fpage>&#8211;<lpage>26</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1532-5415.1968.tb03965.x</pub-id><pub-id pub-id-type="pmid">5634468</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haddow</surname><given-names>A</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>J</given-names></name><name name-style="western"><surname>Graham</surname><given-names>A</given-names></name></person-group>. <article-title>Multiple primary neoplasms in the Western Hospital Region, Scotland: a survey based on cancer registration data</article-title>. <source>Scott Med J</source>. (<year>1972</year>) <volume>17</volume>:<page-range>143&#8211;52</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1177/003693307201700404</pub-id><pub-id pub-id-type="pmid">5023391</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosso</surname><given-names>S</given-names></name><name name-style="western"><surname>Terracini</surname><given-names>L</given-names></name><name name-style="western"><surname>Ricceri</surname><given-names>F</given-names></name><name name-style="western"><surname>Zanetti</surname><given-names>R</given-names></name></person-group>. <article-title>Multiple primary tumors: incidence estimation in the presence of competing risks</article-title>. <source>Population Health metrics</source>. (<year>2009</year>) <volume>7</volume>:<fpage>1</fpage>&#8211;<lpage>10</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/1478-7954-7-5</pub-id><pub-id pub-id-type="pmid">19338658</pub-id><pub-id pub-id-type="pmcid">PMC2682788</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berge</surname><given-names>T</given-names></name><name name-style="western"><surname>Cederqvist</surname><given-names>L</given-names></name><name name-style="western"><surname>Sch&#246;nebeck</surname><given-names>J</given-names></name></person-group>. <article-title>Multiple primary Malignant tumors: an autopsy study of a circumscribed population</article-title>. <source>Acta Pathologica Microbiologica Scandinavica</source>. (<year>1969</year>) <volume>76</volume>:<page-range>171&#8211;83</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1699-0463.1969.tb03248.x</pub-id><pub-id pub-id-type="pmid">5373627</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salem</surname><given-names>A</given-names></name><name name-style="western"><surname>Abu-Hijlih</surname><given-names>R</given-names></name><name name-style="western"><surname>Abdelrahman</surname><given-names>F</given-names></name><name name-style="western"><surname>Turfa</surname><given-names>R</given-names></name><name name-style="western"><surname>Amarin</surname><given-names>R</given-names></name><name name-style="western"><surname>Farah</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Multiple primary Malignancies: analysis of 23 patients with at least three tumors</article-title>. <source>J Gastrointest Cancer</source>. (<year>2012</year>) <volume>43</volume>:<page-range>437&#8211;43</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s12029-011-9296-7</pub-id><pub-id pub-id-type="pmid">21706155</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watanabe</surname><given-names>S</given-names></name><name name-style="western"><surname>Kodama</surname><given-names>T</given-names></name><name name-style="western"><surname>Shimosato</surname><given-names>Y</given-names></name><name name-style="western"><surname>Arimoto</surname><given-names>H</given-names></name><name name-style="western"><surname>Sugimura</surname><given-names>T</given-names></name><name name-style="western"><surname>Suemasu</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Multiple primary cancers in 5,456 autopsy cases in the National Cancer Center of Japan</article-title>. <source>J Natl Cancer Inst</source>. (<year>1984</year>) <volume>72</volume>:<page-range>1021&#8211;7</page-range>.<pub-id pub-id-type="pmid">6585580</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pag&#232;s</surname><given-names>P-B</given-names></name><name name-style="western"><surname>Mordant</surname><given-names>P</given-names></name><name name-style="western"><surname>Grand</surname><given-names>B</given-names></name><name name-style="western"><surname>Badia</surname><given-names>A</given-names></name><name name-style="western"><surname>Foucault</surname><given-names>C</given-names></name><name name-style="western"><surname>Dujon</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>History of multiple previous Malignancies should not be a contraindication to the surgical resection of lung cancer</article-title>. <source>Ann Thorac Surgery</source>. (<year>2013</year>) <volume>95</volume>:<page-range>1000&#8211;5</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.athoracsur.2012.11.072</pub-id><pub-id pub-id-type="pmid">23375734</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomoda</surname><given-names>H</given-names></name><name name-style="western"><surname>Taketomi</surname><given-names>A</given-names></name><name name-style="western"><surname>Baba</surname><given-names>H</given-names></name><name name-style="western"><surname>Kohnoe</surname><given-names>S</given-names></name><name name-style="western"><surname>Seo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Saito</surname><given-names>T</given-names></name></person-group>. <article-title>Multiple primary colorectal and gastric carcinoma in Japan</article-title>. <source>Oncol Rep</source>. (<year>1998</year>) <volume>5</volume>:<page-range>147&#8211;56</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.3892/or</pub-id><pub-id pub-id-type="pmid">9458311</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khader</surname><given-names>YS</given-names></name><name name-style="western"><surname>Sharkas</surname><given-names>GF</given-names></name><name name-style="western"><surname>Arkoub</surname><given-names>KH</given-names></name><name name-style="western"><surname>Alfaqih</surname><given-names>MA</given-names></name><name name-style="western"><surname>Nimri</surname><given-names>OF</given-names></name><name name-style="western"><surname>Khader</surname><given-names>AM</given-names></name></person-group>. <article-title>The epidemiology and trend of cancer in Jordan, 2000&#8211;2013</article-title>. <source>J Cancer Epidemiol</source>. (<year>2018</year>) <volume>2018</volume>. doi:&#160;<pub-id pub-id-type="doi">10.1155/2018/2937067</pub-id><pub-id pub-id-type="pmcid">PMC6207872</pub-id><pub-id pub-id-type="pmid">30416523</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soerjomataram</surname><given-names>I</given-names></name><name name-style="western"><surname>Coebergh</surname><given-names>JW</given-names></name></person-group>. <article-title>Epidemiology of multiple primary cancers</article-title>. <source>Cancer Epidemiol</source>. (<year>2009</year>) <fpage>85</fpage>&#8211;<lpage>105</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/978-1-59745-416-2_5</pub-id><pub-id pub-id-type="pmid">19109776</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y-K</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>FT</given-names></name><name name-style="western"><surname>Sung</surname><given-names>F</given-names></name><name name-style="western"><surname>Kao</surname><given-names>C</given-names></name></person-group>. <article-title>Cancer risk in patients with Hashimoto&#8217;s thyroiditis: a nationwide cohort study</article-title>. <source>Br J Cancer</source>. (<year>2013</year>) <volume>109</volume>:<page-range>2496&#8211;501</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/bjc.2013.597</pub-id><pub-id pub-id-type="pmcid">PMC3817335</pub-id><pub-id pub-id-type="pmid">24084773</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albright</surname><given-names>F</given-names></name><name name-style="western"><surname>Teerlink</surname><given-names>C</given-names></name><name name-style="western"><surname>Werner</surname><given-names>TL</given-names></name><name name-style="western"><surname>Cannon-Albright</surname><given-names>LA</given-names></name></person-group>. <article-title>Significant evidence for a heritable contribution to cancer predisposition: a review of cancer familiarity by site</article-title>. <source>BMC Cancer</source>. (<year>2012</year>) <volume>12</volume>:<fpage>1</fpage>&#8211;<lpage>7</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/1471-2407-12-138</pub-id><pub-id pub-id-type="pmid">22471249</pub-id><pub-id pub-id-type="pmcid">PMC3350420</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Artac</surname><given-names>M</given-names></name><name name-style="western"><surname>Bozcuk</surname><given-names>H</given-names></name><name name-style="western"><surname>Ozdogan</surname><given-names>M</given-names></name><name name-style="western"><surname>Demiral</surname><given-names>AN</given-names></name><name name-style="western"><surname>Sarper</surname><given-names>A</given-names></name><name name-style="western"><surname>Samur</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Different clinical features of primary and secondary tumors in patients with multiple Malignancies</article-title>. <source>Tumori J</source>. (<year>2005</year>) <volume>91</volume>:<page-range>317&#8211;20</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1177/030089160509100406</pub-id><pub-id pub-id-type="pmid">16277096</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cameselle-Teijeiro</surname><given-names>JM</given-names></name><name name-style="western"><surname>Peteiro-Gonz&#225;lez</surname><given-names>D</given-names></name><name name-style="western"><surname>Caneiro-G&#243;mez</surname><given-names>J</given-names></name><name name-style="western"><surname>S&#225;nchez-Ares</surname><given-names>M</given-names></name><name name-style="western"><surname>Abdulkader</surname><given-names>I</given-names></name><name name-style="western"><surname>Eloy</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Cribriform-morular variant of thyroid carcinoma: a neoplasm with distinctive phenotype associated with the activation of the WNT/&#946;-catenin pathway</article-title>. <source>Mod Pathol</source>. (<year>2018</year>) <volume>31</volume>:<page-range>1168&#8211;79</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41379-018-0070-2</pub-id><pub-id pub-id-type="pmid">29785019</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nielsen</surname><given-names>SM</given-names></name><name name-style="western"><surname>White</surname><given-names>MG</given-names></name><name name-style="western"><surname>Hong</surname><given-names>S</given-names></name><name name-style="western"><surname>Aschebrook-Kilfoy</surname><given-names>B</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>EL</given-names></name><name name-style="western"><surname>Angelos</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>The breast&#8211;thyroid cancer link: a systematic review and meta-analysis</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source>. (<year>2016</year>) <volume>25</volume>:<page-range>231&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1158/1055-9965.EPI-15-0833</pub-id><pub-id pub-id-type="pmcid">PMC4770576</pub-id><pub-id pub-id-type="pmid">26908594</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>An</surname><given-names>JH</given-names></name><name name-style="western"><surname>Hwangbo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>HY</given-names></name><name name-style="western"><surname>Keam</surname><given-names>B</given-names></name><name name-style="western"><surname>Lee</surname><given-names>KE</given-names></name><name name-style="western"><surname>Han</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>A possible association between thyroid cancer and breast cancer</article-title>. <source>Thyroid</source>. (<year>2015</year>) <volume>25</volume>:<page-range>1330&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1089/thy.2014.0561</pub-id><pub-id pub-id-type="pmid">26442580</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>L</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>B</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name></person-group>. <article-title>Review of the possible association between thyroid and breast carcinoma</article-title>. <source>World J Surg Oncol</source>. (<year>2018</year>) <volume>16</volume>:<fpage>1</fpage>&#8211;<lpage>7</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12957-018-1436-0</pub-id><pub-id pub-id-type="pmid">29976206</pub-id><pub-id pub-id-type="pmcid">PMC6034293</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lei</surname><given-names>K</given-names></name><name name-style="western"><surname>He</surname><given-names>X</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L</given-names></name><name name-style="western"><surname>Ni</surname><given-names>C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Guan</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Breast cancer prognosis is better in patients who develop subsequent metachronous thyroid cancer</article-title>. <source>PloS One</source>. (<year>2019</year>) <volume>14</volume>:<elocation-id>e0215948</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0215948</pub-id><pub-id pub-id-type="pmid">31042767</pub-id><pub-id pub-id-type="pmcid">PMC6493754</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>F</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Synchronous double primary lymphoma and thyroid cancer: A single-institution retrospective study</article-title>. <source>Medicine</source>. (<year>2021</year>) <volume>100</volume>. doi:&#160;<pub-id pub-id-type="doi">10.1097/MD.0000000000027061</pub-id><pub-id pub-id-type="pmcid">PMC8483851</pub-id><pub-id pub-id-type="pmid">34596109</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schaapveld</surname><given-names>M</given-names></name><name name-style="western"><surname>Aleman</surname><given-names>BM</given-names></name><name name-style="western"><surname>van Eggermond</surname><given-names>AM</given-names></name><name name-style="western"><surname>Janus</surname><given-names>CP</given-names></name><name name-style="western"><surname>Krol</surname><given-names>AD</given-names></name><name name-style="western"><surname>van der Maazen</surname><given-names>RW</given-names></name><etal/></person-group>. <article-title>Second cancer risk up to 40 years after treatment for Hodgkin&#8217;s lymphoma</article-title>. <source>N Engl J Med</source>. (<year>2015</year>) <volume>373</volume>:<page-range>2499&#8211;511</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa1505949</pub-id><pub-id pub-id-type="pmid">26699166</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sigurdson</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Ronckers</surname><given-names>CM</given-names></name><name name-style="western"><surname>Mertens</surname><given-names>AC</given-names></name><name name-style="western"><surname>Stovall</surname><given-names>M</given-names></name><name name-style="western"><surname>Smith</surname><given-names>SA</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Primary thyroid cancer after a first tumor in childhood (the Childhood Cancer Survivor Study): a nested case-control study</article-title>. <source>Lancet</source>. (<year>2005</year>) <volume>365</volume>:<page-range>2014&#8211;23</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(05)66695-0</pub-id><pub-id pub-id-type="pmid">15950715</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liou</surname><given-names>M-J</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>N-M</given-names></name><name name-style="western"><surname>Hsueh</surname><given-names>C</given-names></name><name name-style="western"><surname>Chao</surname><given-names>T-C</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J-D</given-names></name></person-group>. <article-title>Therapeutic outcome of second primary Malignancies in patients with well-differentiated thyroid cancer</article-title>. <source>Int J Endocrinol</source>. (<year>2016</year>) <volume>2016</volume>. doi:&#160;<pub-id pub-id-type="doi">10.1155/2016/9570171</pub-id><pub-id pub-id-type="pmcid">PMC4828550</pub-id><pub-id pub-id-type="pmid">27118971</pub-id></mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lang</surname><given-names>BH-H</given-names></name><name name-style="western"><surname>Wong</surname><given-names>KP</given-names></name></person-group>. <article-title>Risk factors for nonsynchronous second primary Malignancy and related death in patients with differentiated thyroid carcinoma</article-title>. <source>Ann Surg Oncol</source>. (<year>2011</year>) <volume>18</volume>:<page-range>3559&#8211;65</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1245/s10434-011-1777-1</pub-id><pub-id pub-id-type="pmcid">PMC3222830</pub-id><pub-id pub-id-type="pmid">21573833</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>